

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/70, 31/715, 31/725, 9/127	A1	(11) International Publication Number: WO 98/37902 (43) International Publication Date: 3 September 1998 (03.09.98)
(21) International Application Number: PCT/US98/03957 (22) International Filing Date: 27 February 1998 (27.02.98) (30) Priority Data: 60/039,564 28 February 1997 (28.02.97) US Not furnished 27 February 1998 (27.02.98) US (71) Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US/US]; 21st floor, 300 Lakeside Drive, Oakland CA 94612-3550 (US). (72) Inventors: NAGY, Jon, O.; 120 Bonita Court, Rodeo, CA 94572 (US). BARGATZE, Robert, F.; 1302 Wildflower Way, Bozeman, MT 59715 (US). (74) Agents: MACKNIGHT, Kamrin, T.; Medlen & Carroll, LLP, Suite 2200, 220 Montgomery Street, San Francisco, CA 94104 (US) et al.		(81) Designated States: AU, CA, JP, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: INHIBITION OF CELL-CELL BINDING BY LIPID ASSEMBLIES (57) Abstract This invention relates generally to the field of therapeutic compounds designed to interfere between the binding of ligands and their receptors on cell surface. More specifically, it provides products and methods for inhibiting cell migration and activation using lipid assemblies with surface recognition elements that are specific for the receptors involved in cell migration and activation.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		

INHIBITION OF CELL-CELL BINDING BY LIPID ASSEMBLIES

This application claims priority benefit of U.S. provisional application No. 60/039,564, filed February 28, 1997, pending, which is hereby incorporated herein by reference in its entirety.

This invention was made in part during work partially supported by the U.S. Department of Energy under contract DE-AC03-76SF00098. The government has certain rights in the invention.

FIELD OF THE INVENTION

This invention relates generally to the field of therapeutic compounds designed to interfere between the binding of ligands and their receptors on cell surface. More specifically, it provides products and methods for inhibiting cell migration and activation using lipid assemblies with surface recognition elements that are specific for the receptors involved in cell migration and activation.

BACKGROUND OF THE INVENTION

The adhesion of circulating neutrophils to endothelial cells is one of the important events occurring in the process of inflammation. Neutrophil recruitment to tissues is initiated by an adhesion cascade. Through this process, cells roll and eventually attach firmly to the endothelium. The factors that contribute to the high binding strength of this interaction are not fully understood, but is thought to involve interaction between selectins on one cell with carbohydrate ligands on another cell. By interfering with the binding between these components, it may be possible to counter pathological conditions related to cell migration.

A number of adhesion molecules mediate the interaction of neutrophils and other leukocytes to the endothelium. Amongst them are the ICAMs, VCAM, CD11, CD18, the integrin $\alpha 4\beta 1$, and several receptors now known collectively as selectins. Each of these molecules is part of a ligand-receptor pair, one of which is expressed on each of the two interacting cells. For a general review, the reader is referred to Bevilacqua (Ann. Rev. Immunol. 11:767, 1993). In various combinations, these and other molecules support leukocyte adhesion to the vessel wall and extravasation, and may also participate in activation of cell effector functions. Expression of many of these molecules is up-regulated by soluble

factors such as cytokines, thereby acting to increase the recruitment of leukocytes to an affected area.

Amongst the plurality of adhesion molecules that have been described, three have been collected together in a category known as selectins. One was formerly known as ELAM-1, and was identified using inhibitory monoclonal antibodies against cytokine-activated endothelial cells, and is now known as E-selectin. Another was formerly designated as PADGEM, GMP-140, or CD61. It was originally identified on platelets, and is now known as P-selectin. A third identified on lymphocytes was formerly designated as mLHR, Leu8, TQ-1, gp90^{MEL}, Lam-1, or Lecam-1, and is now known as L-selectin. The selectins were grouped together on the basis of a structural similarity, before very much was known about their binding specificity. All are single chain polypeptides having a carbohydrate binding domain near the N-terminus, an EGF repeat, and anywhere between 2 to 9 modules of approximately 60 amino acids each sharing homology with complement binding proteins. For general reviews, the reader is referred to Lasky (Ann. Rev. Biochem. 64:113, 1995) and Kansas (Blood 88:3259, 1996).

The three selectins differ from each other in a number of important respects. As depicted schematically in Figure 3, the selectins have different ligand counterparts in the adhesion process. Each selectin is regulated differently, and participates in a different manner in the process of inflammation or immunity. There is also an increasing appreciation for differences in the ligand binding requirements between the selectins.

E-selectin has garnered a significant amount of recent research interest because of its role in inflammation. The migration of inflammatory mediator cells to an inflammatory site is thought to be mediated in part by adhesion of the cells to vascular endothelial cells. Studies *in vitro* have suggested that E-selectin participates in the adhesion of not only neutrophils, but also eosinophils, monocytes and a subpopulation of memory T-cells to endothelium that has been activated by endotoxin, IL-1, or TNF. Expression of E-selectin by endothelial monolayer increases by about 10-fold and peaks at about 4 hours after stimulation with IL-1, subsiding to near basal levels within 24 hours. The biological role of E-selectin is thought to be a strong binding of cells bearing a suitable E-selectin ligand, over a time-course of 20 minutes to 1 hour, particularly during the course of local inflammation.

Phillips *et al.* (Science 250:1130, 1990) first identified the binding target of E-selectin as the oligosaccharide sialyl Lewis X (sLe^x) (NeuAc α 2,3Gal β 1,4(fuc α 1,3)GlcNac-), a terminal structure found on the cell surface glycoprotein of neutrophils. This has become the

prototype carbohydrate ligand for the selectin class. This and related oligosaccharides are the subject of U.S. Patent 5,576,305 and PCT application WO 92/07572.

The sLe^x unit has been assembled into various polymeric structures in an attempt to improve its weak binding to selectins. For example, U.S. Patent 5,470,843 and DeFrees *et al.* (J. Am. Chem. Soc. 117:66, 1995) disclose bivalent sialyl X saccharides. U.S. Patent 5,470,843 discloses a carbohydrate-containing polymer having a synthetic polymer backbone with 10-20 sLe^x, sLe^a, or GlcNac linked via a bifunctional spacer.

DeFrees *et al.* (J. Am. Chem. Soc. 118:6101, 1996) describe a sLe^x preparation made with conventional phospholipid liposome technology. The liposomes contain phosphatidylcholine, cholesterol, phospholipid conjugated with methoxypolyethylene glycol, and phospholipid conjugated with sLe^x through a polyethylene glycol spacer. Data is presented showing that this composition is 5×10^3 fold more potent than the sLe^x monomer in inhibiting the binding of E-selectin to cells. Murohara *et al.* (Cardiovasc. Res. 30:965, 1995) tested sLe^x phospholiposomes in a myocardial reperfusion model, and found that a dose of 400 µg/kg body weight reduced the proportional size of the area of risk and necrosis.

P-selectin is a transmembrane glycoprotein of approximately 140 kDa, substantially larger than E-selectin. It was originally described on platelets, in which it may be found in α - and dense-granules. Upon activation of platelets with a mediator like thrombin, P-selectin is rapidly redistributed to the cell surface. In endothelial cells, it is found in granules known as Weibel-Palade bodies, from which it is redistributed to the surface upon activation with histamine. Shuttling of P-selectin to storage granules appears to be mediated by a sorting signal present in the cytoplasmic domain, and apparently unique in comparison with E-selectin.

Accordingly, P-selectin differs from E-selectin in that it may be rapidly expressed from storage granules rather than requiring *de novo* synthesis. P-selectin binds carbohydrate ligands present on neutrophils, monocytes, and memory T cells. Not only is P-selectin in a preformed state, its expression is stimulated by mediators such as histamine which in turn are preformed and stored in the granules of inflammatory cells. The adherence of leukocytes to P-selectin rather than E-selectin on endothelial cells is perhaps the initial event that occurs for recruitment of leukocyte cells to an injured site. Interference with P-selectin binding may be particularly important when it is desirable to limit leukocyte migration.

The presence of P-selectin on platelets suggests additional unique biological roles compared with the other selectins. In one hypothesis, sites of tissue injury may be acutely

enriched with short-acting platelet activators, and active platelets expressing P-selectin may directly recruit other leukocytes. In another hypothesis, neutrophils or monocytes at an inflamed site may be able to catch platelets by way of the P-selectin, which in turn could lead to clot formation or additional mediator release. In an experimental thrombus model, it has been observed that platelets accumulate first at the injury site, followed by leukocyte adherence and fibrin deposition. Both of the latter two steps was inhibited by antibodies against P-selectin (Palabrica *et al.*, Nature, 359:848, 1992).

L-selectin has a number of features that are different from the other known selectins. First, the tissue distribution pattern is opposite to that of P- and E-selectin--it is expressed on the surface of leukocytes, rather than on the endothelium; while the ligand it binds to is on the endothelium rather than the leukocytes. Second, L-selectin is constitutively expressed, rather than being up-regulated during inflammation, and is shed following activation. This may act to allow the activated cells to be released after binding, or may indicate a role of L-selectin in cellular activation. Third, L-selectin is present not only on neutrophils and monocytes, but also on most lymphocytes; while the ligand counterpart is present not only on endothelium but also on lymph node HEV. L-selectin appears to play a key role in homing to lymph nodes (Shimizu *et al.*, Immunol. Today 13:106, 1992; Picker *et al.*, Annu. Rev. Immunol. 10:561, 1992). In pathological conditions involving the immune system, it may be L-selectin that plays the most central role.

U.S. Patent 5,489,578 describes sulfated ligands for L-selectin and methods of treating inflammation. The ligands are sulfooligosaccharides based on the carbohydrate structures present on the natural L-selectin ligand GlyCAM-1.

U.S. Patent 5,486,536 describes the use of sulfatides as anti-inflammatory compounds. The binding activity was attributed to a critical sulfate group at position 3 on the pyranose ring of galactose. In one experiment, sulfatides were sonicated in a protein-containing buffer to produce microdroplets. The preparation was asserted to have protective effects in two animal models for acute lung injury and inflammation.

Each of the selectins shows specificity in terms of the carbohydrate requirements for binding. All three selectins bind sialylated fucooligosaccharides, of which the prototype is the tetrasaccharide sialyl Lewis^x (sLe^x). Direct binding experiments between synthetic carbohydrates and isolated selectins has permitted a more detailed dissection of the binding requirements (e.g., Brandley *et al.*, Glycolbiology 3:633, 1993). E- and L-selectin require an α 2-3 linkage for the sialic acid in sLe^x, whereas P-selectin can recognize sialic acid in an α 2-

6 linkage. P-selectin also does not require a hydroxyl group in the fucose 2- and 4- positions. P- and L-selectin bind sulfated structures like sulpho-Le^x-(Glc)-cer and sulfatides in a manner largely independent of divalent cations, whereas E-selectin binding is sensitive to the presence of cations. Binding of P- and L-selectin to sulfated carbohydrates can only be inhibited by other sulfated carbohydrates, whereas E-selectin does not have this requirement.

It is important to emphasize that the selectin specificity in biological reactions appears to be mediated by more than the carbohydrate component of the ligand. For example, P- and L-selectin (but not E-selectin) bind sulfated molecules that lack sialic acid and fucose, such as sulfatides (Aruffo *et al.*, Cell 67:35, 1991) and certain subspecies of heparin (Norgard-Sumnicht *et al.*, Science 261:480, 1993). For a general review of the variety of carbohydrates recognized by the selectins, see Varki *et al.* (Proc. Natl. Acad. Sci. USA 91:7390, 1994).

Each of the selectins has a different family of natural ligands on the surface of the opposing cell (*See e.g.*, McEver *et al.*, 270:11025, 1995). E-selectin binds strongly to a ligand designated ESL-1. In contrast, antibody blocking studies indicate that essentially all the binding sites for P-selectin on leukocytes are attributable to an O-glycosylated protein designated P-selectin glycoprotein ligand 1 (PSGL-1) (Moore *et al.*, J. Cell Biol. 128:661, 1995). The natural ligands identified for L-selectin is neither of these, but include other glycoproteins with the designations GlyCAM-1, CD34, and MAdCAM-1.

The binding specificity indicates that at least two of the three selectins must be recognizing a ligand component beyond the sLe^x structure. In addition to the oligosaccharide, P-selectin must bind a site on PSGL-1 with features different from ESL-1 and from other mucin-like O-glycosylated proteins, such as CD43.

A second ligand requirement for high affinity binding of the natural ligand has been identified for both P- and L-selectin. The second requirement is a sulfate residue, which is apparently not required for E-selectin binding, and has implications for the development of effective inhibitory compounds.

Imai *et al.* (Nature 361:555, 1993) tested the requirements for binding of L-selectin to the ligands on lymph node HEV. Radioactive inorganic sulfate is incorporated into the 50 kDa and 90 kDa glycoproteins in a manner that can be inhibited by sodium chlorate. The undersulfated glycoproteins no longer interacted in precipitation analyses with an L-selectin chimera. The inhibition experiments do not pinpoint the location of the required sulfate

group to the carbohydrate or the protein backbone. Either way, the sulfate requirement distinguishes L-selectin binding specificity from that of E-selectin.

The sulfate component has been mapped more precisely in the structure of the P-selectin ligand PSGL-1. The requirement in P-selectin is provided by one or more sulfated tyrosines near the N-terminus of the polypeptide backbone, separate from the glycosylation site.

Wilkins *et al.* (J. Biol. Chem. 270:22677, 1995) demonstrated that PSGL-1 synthesized in human HL-60 cells can be metabolically labeled with [³⁵S]sulfate. It was shown that most of the ³⁵S label was incorporated into the polypeptide in the form of tyrosine sulfate. Treatment of PSGL-1 with a bacterial arylsulfatase released sulfate from tyrosine, and resulted in a concordant decrease in binding to P-selectin.

Pouyani *et al.* (Cell 83:333, 1995) demonstrated that selective inhibitors of sulfation compromised binding of HL-60 cells to soluble P-selectin but not E-selectin. The cell-surface expression of sLe^x or the polypeptide were not compromised by treatment. Deletion analysis of isolated PSGL-1 constructs localized the binding component to residues 20-40. The segment contains three tyrosine residues, and when these were changed to phenylalanine, P-selectin binding activity was abolished. Furthermore, when the 20 amino acid segment was fused onto a different protein, it was again sulfated during biosynthesis and had binding activity for P-selectin. These authors suggested that the sulfated tyrosines interact with P-selectin not through the carbohydrate binding domain of P-selectin, but through the EGF-like domain, which is located closer in the protein sequence to the membrane spanning domain.

Sako *et al.* (Cell 83:323, 1995) performed another series of binding experiments using the extracellular domain of PSGL-1 expressed as a fusion protein. The assay required fucosylation of the protein and cations in the assay medium, consistent with a dependence on carbohydrates like sLe^x. Mutation of the putative N-linked glycosylation sites had no effect on selectin binding, suggesting that the carbohydrate requirement was O-linked. However, mutation of three tyrosines to phenylalanine abrogated binding activity for P-selectin. Binding of E-selectin, for which PSGL-1 can also act as a ligand, was not affected by removal of the sulfation sites.

The binding affinity of P- and L-selectin for sLe^x is in the mM range (Nelson *et al.*, J. Clin. Invest. 91:1157, 1993). In contrast, the affinity of P-selectin for the natural ligand is in the nM range (Moore *et al.*, J. Cell Biol. 112:491, 1991), a difference in potency of approximately 10⁶ fold. Synthetic oligosaccharides containing multiple sLe^x units only partly

make up the difference, so the effect is not just due to ligand valency. The disparity is also attributable to the requirement of P- and L-selectin for a strong anionic determinant, like the sulfotyrosines on PSGL-1. Compounds effective in the same concentration range as PSGL-1 must be able to supply a similarly effective determinant combination.

5 There is a need to develop new therapeutic compositions capable of interfering with selectin-ligand interactions, because cellular adhesion is an early event in a number of inflammatory and immunological phenomena. For systemic administration, the compositions should be effective in the nanomolar range, so that an effective amount can be given in a practicable dose. It is important to emphasize that putative compositions should be tested in a
10 system that adequately represents the requirements of the natural interaction. A one-component inhibitor that effectively blocks a one-component interaction will typically not be effective in blocking a two-component interaction.

SUMMARY OF THE INVENTION

15 This invention relates generally to the field of therapeutic compounds designed to interfere between the binding of ligands and their receptors on cell surface. More specifically, it provides products and methods for inhibiting cell migration and activation using lipid assemblies with surface recognition elements that are specific for the receptors involved in cell migration and activation.

20 The presently claimed invention provides compositions comprising lipid assemblies, wherein the lipid assemblies comprise a plurality of lipid monomers, one or more surface exposed oxyacid groups, and one or more surface exposed carbohydrates, and wherein the lipid assemblies are capable of inhibiting the binding between a first cell having a receptor and a second cell having a ligand for the receptor.

25 In some embodiments, the compositions comprise surface exposed oxyacid group selected from the group consisting of carboxyl groups and groups of the form $(XO_n)(O^-)_p$, where $n+p>2$ and X is an atom capable of binding three or more oxygen atoms. In preferred embodiments, X is a sulphur or phosphorus atom. The surface exposed oxyacid group can be covalently attached to the lipid monomers of the lipid assemblies, although the presently
30 claimed invention also contemplates embodiments where the oxyacid groups are not covalently attached to the monomers.

 In some embodiments, the compositions comprise surface exposed carbohydrates comprising neutral carbohydrates. In preferred embodiments, these neutral carbohydrates are

selected from the group consisting of maltose and lactose. As with the oxyacid groups, the surface exposed carbohydrates can be covalently attached to the lipid monomers, although the presently claimed invention also contemplates embodiments where the carbohydrates are not covalently attached to the monomers.

5 In some embodiments, the receptor on the first cell comprises a selectin. These selectins include but are not limited to P-selectin, L-selectin, and E-selectin. In other embodiments, the receptor is selected from the group consisting of lectins, heparin, heparan sulfate, gangliosides, glycans, glycoproteins, and glycolipids.

10 The presently claimed invention further provides compositions comprising one or more polymerized lipid assemblies, wherein the polymerized lipid assemblies comprise a plurality of lipid monomers and one or more surface exposed oxyacid groups, and wherein the polymerized lipid assemblies are capable of inhibiting the binding between a first cell having a receptor and a second cell having a ligand for the receptor.

15 In some embodiments, these compositions further comprise one or more surface exposed carbohydrates. In preferred embodiments, these surface exposed carbohydrates are selected from the group consisting of sulfated carbohydrates, fucose, sialylated fucooligosaccharides, sialylated fucooligosaccharide analogs, sulfated fucooligosaccharides, maltose, lactose, sialic acid, glycopeptides, and combinations thereof. The surface exposed carbohydrates can be covalently attached to the lipid monomers, although the presently
20 claimed invention also contemplates embodiments where the carbohydrates are not covalently attached to the monomers.

In some embodiments, the compositions comprise surface exposed oxyacid group comprises groups of the form $(XO_n)(O^-)_p$ where $n+p>2$ and X is an atom capable of binding three or more oxygen atoms. In preferred embodiments, X is a sulphur or phosphorus atom.
25 The surface exposed oxyacid group can be covalently attached to the lipid monomers of the lipid assemblies, although the presently claimed invention also contemplates embodiments where the oxyacid groups are not covalently attached to the monomers.

The presently claimed invention also provides methods for inhibiting the binding between a first cell having a receptor and a second cell having a ligand for the receptor.
30 comprising providing a sample containing the first cell and the second cell, and a polymerized lipid assembly comprising a plurality of lipid monomers and one or more surface exposed oxyacid groups; and exposing the polymerized lipid assembly to the first cell. In some embodiment, the inhibition of the binding between the first and second cells comprises

inhibition of cell-cell interactions including, but not limited to, cell adhesion and cell migration.

In some embodiments, the polymerized lipid assemblies of these methods further comprise one or more surface exposed carbohydrates. In preferred embodiments, these surface exposed carbohydrates are selected from the group consisting of sulfated carbohydrates, fucose, sialylated fucooligosaccharides, sialylated fucooligosaccharide analogs, sulfated fucooligosaccharides, maltose, lactose, sialic acid, glycopeptides, and combinations thereof. The surface exposed carbohydrates can be covalently attached to the lipid monomers, although the presently claimed invention also contemplates embodiments where the carbohydrates are not covalently attached to the monomers.

In some embodiments, the polymerized lipid assemblies of these methods comprise surface exposed oxyacid group comprises groups of the form $(XO_n)(O^-)_p$ where $n+p>2$ and X is an atom capable of binding three or more oxygen atoms. In preferred embodiments, X is a sulphur or phosphorus atom. The surface exposed oxyacid group can be covalently attached to the lipid monomers of the lipid assemblies, although the presently claimed invention also contemplates embodiments where the oxyacid groups are not covalently attached to the monomers.

The presently claimed invention further provides methods for inhibiting the binding between a first cell having a receptor and a second cell having a ligand for the receptor, comprising providing a sample containing the first cell and the second cell, and a lipid assembly comprising a plurality of lipid monomers, one or more surface exposed oxyacid groups, and one or more surface exposed carbohydrates; and exposing the polymerized lipid assembly to the first cell. In some embodiment, the inhibition of the binding between the first and second cells comprises inhibition of cell-cell interactions including, but not limited to, cell adhesion and cell migration.

In some embodiments, the lipid assemblies of these methods comprise surface exposed oxyacid group selected from the group consisting of carboxyl groups and groups of the form $(XO_n)(O^-)_p$ where $n+p>2$ and X is an atom capable of binding three or more oxygen atoms. In preferred embodiments, X is a sulphur or phosphorus atom. The surface exposed oxyacid group can be covalently attached to the lipid monomers of the lipid assemblies, although the presently claimed invention also contemplates embodiments where the oxyacid groups are not covalently attached to the monomers.

In some embodiments, the lipid assemblies of these methods comprise surface exposed carbohydrates comprising neutral carbohydrates. In preferred embodiments, these neutral carbohydrates are selected from the group consisting of maltose and lactose. As with the oxyacid groups, the surface exposed carbohydrates can be covalently attached to the lipid monomers, although the presently claimed invention contemplates embodiments where the carbohydrates are not covalently attached to the monomers.

The presently claimed invention further provides methods of inhibiting the binding between a first cell having a receptor and a second cell having a ligand for said receptor, comprising providing a sample containing the first cell and the second cell, and a means for inhibiting the binding between the first cell and the second cell; and exposing the means for inhibiting the binding between the first cell and the second cell to the first cell.

DESCRIPTION OF THE FIGURES

Figure 1 is a drawing of two exemplary polymerized liposomes of the present invention showing an expanded detail of the chemical structure. Structure "A" comprises sulfate lipids, and Structure "B" comprises phosphate lipids. Liposomes with 50% sulfate (Structure "A") inhibit the binding of P- and L-selectin to carbohydrate-bearing mucins at a level comparable with some oligosaccharide-conjugated liposomes and more effectively than monomeric oligosaccharides.

Figure 2 is a drawing of polymerized liposomes comprising: "A" lipids with carbohydrate and carboxylic acid head groups; and "B" lipids with carbohydrate and uncharged headgroups.

Figure 3 is a schematic depicting some of the aspects of selectin binding. The boxed panel shows the receptor ligand pairs known for L-, P- and E-selectin. They are depicted on the same cell for convenience, but participate in different ways to cell adhesion and migration. Below is a model showing the dual binding site for P-selectin. In the ligand PSGL-1, the negative groups correspond to three sulfotyrosine residues.

Figure 4 is a drawing of particular components that may be chosen for assembly into lipid assemblies.

Figure 5 is a titration curve for the inhibition of P-selectin binding to HL-60 cells by glycoliposomes. In order of decreasing potency (left to right) the compositions are comprised of: sLe^x analog plus acidic lipids (triangles); lactose plus acidic lipids (closed circles); maltose plus acidic lipids (boxes); and sLe^x analog plus neutral lipids (open circles).

Figure 6 is a bar graph showing the 50% inhibition concentration of various liposome preparations.

Figure 7 is a drawing of the polymerized liposomes tested for binding in Example 3. Amongst the components tested, the sulfo Le^x analog was found to be the best carbohydrate, and lipid with a sulfate group best fulfilled the requirement for a separate negatively charged group in this GlyCAM-1 ELISA experiment.

Figures 8 and 9 are drawings of additional exemplary carbohydrate determinants for inclusion in polymerized glycoliposomes.

Figure 10 is a drawing comparing the sLe^x structure and an sLe^x tethered analog with a novel glycoliposome comprising sialic acid and fucose residues on neighboring lipids in the crosslinked matrix.

Figure 11 shows bar graphs for rolling cell inhibition assays for: A) IL-1 β activated HUVEC cell rolling; B) neutrophil rolling; C) thrombin activated platelet rolling; and D) neutrophil/neutrophil rolling.

Figure 12 is a graph showing the effects of sLe^x analog and sLe^x-like groups on activated endothelial neutrophil adhesion in rolling cell assays.

Figure 13 is a graph showing the effects of sLe^x analog and sLe^x-like groups on activated platelet leukocyte adhesion.

DEFINITIONS

To facilitate an understanding of the present invention, a number of terms and phrases are defined below:

As used herein, the term "selective binding" refers to the binding of one material to another in a manner dependent upon the presence of a particular molecular structure (*i.e.*, specific binding). For example, a receptor will selectively bind ligands that contain the chemical structures complementary to the ligand binding site(s). This is in contrast to "non-selective binding," whereby interactions are arbitrary and not based on structural compatibilities of the molecules.

As used herein, the term "membrane" refers to, in one sense, a sheet or layer of material. It is intended that the term encompass all "biomembranes" (*i.e.*, any organic membrane including, but not limited to, plasma membranes, nuclear membranes, organelle membranes, and synthetic membranes). Typically, membranes are composed of lipids, proteins, glycolipids, steroids, sterols and/or other components. As used herein, the term

"membrane fragment" refers to any portion or piece of a membrane. The term "polymerized membrane" refers to membranes that have undergone partial or complete polymerization.

As used herein, the term "polymerization" encompasses any process that results in the conversion of small molecular monomers into larger molecules consisting of repeated units. Typically, polymerization involves chemical crosslinking of molecular monomers to one another.

As used herein, the term "drug" refers to a substance or substances that are used to diagnose, treat, or prevent diseases or conditions. Drugs act by altering the physiology of a living organism, tissue, cell, or *in vitro* system that they are exposed to. It is intended that the term encompass antimicrobials, including, but not limited to, antibacterial, antifungal, and antiviral compounds. It is also intended that the term encompass antibiotics, including naturally occurring, synthetic, and compounds produced by recombinant DNA technology.

As used herein, the term "carbohydrate" refers to a class of molecules including, but not limited to, sugars, starches, cellulose, chitin, glycogen, and similar structures. Carbohydrates can also exist as components of glycolipids and glycoproteins. As used herein, the term "neutral carbohydrate" refers to carbohydrates that possess a net charge of zero. Such carbohydrates include, but are not limited to, lactose, maltose, and sucrose.

As used herein, the term "lipid" refers to a variety of compounds that are characterized by their solubility in organic solvents. Such compounds include, but are not limited to, fats, waxes, steroids, sterols, glycolipids, glycosphingolipids (including gangliosides), phospholipids, terpenes, fat-soluble vitamins, prostaglandins, carotenes, and chlorophylls. As used herein, the terms "lipid-based materials" and "lipid assemblies" refers to any material that contains lipids. In some embodiments, "lipid assemblies" are structures including, but not limited to vesicles, liposomes, films, micelles, dendrimers, monolayers, bilayers, tubules, rods, and coils. As used herein, the term "lipid monomer" refers to a single lipid molecule. Lipid monomers include lipids that are covalently or otherwise attached to ligands or other chemical groups. In some embodiments, lipid monomers contain polymerizable groups.

As used herein, the term "surface exposed" refers to molecules that are present (*e.g.*, accessible to receptor/ligand interactions) at the surface of a structure (*e.g.*, a lipid assembly).

As used herein, the term "vesicle" refers to a small enclosed structures. Often the structures are membranes composed of lipids, proteins, glycolipids, steroids or other components associated with membranes. Vesicles can be naturally generated (*e.g.*, the

vesicles present in the cytoplasm of cells that transport molecules and partition specific cellular functions) or can be synthetic (*e.g.*, liposomes).

As used herein, the term "liposome" refers to artificially produced spherical lipid complexes that can be induced to segregate out of aqueous media. The term
5 "glycoliposomes" refers to liposomes containing carbohydrates. The phrase "two-component glycoliposome" refers to glycoliposomes comprising two distinct chemical entities (*e.g.*, carbohydrate linked lipids and lipids with polar head groups).

As used herein, the term "lipid sheet" refers to a region of lipid material that provides a surface for receptor/ligand interactions. A lipid sheet may comprise monolayer and bilayer
10 films or may be present within three-dimensional assemblies such as liposomes, micelles, tubules, coils, rods, or other forms.

As used herein, the term "micelle" refers to a particle of colloidal size that has a hydrophilic exterior and hydrophobic interior.

As used herein, the term "ligands" refers to any ion, molecule, molecular group, or
15 other substance that binds to another entity (*e.g.*, receptor) to form a larger complex. Examples of ligands include, but are not limited to, peptides, carbohydrates, nucleic acids, antibodies, or any molecules that bind to receptors.

As used herein, the term "head group" refers to the molecular group present at the ends of molecules (*e.g.*, the carboxylic acid group at the end of fatty acids).

As used herein, the term "oxyacid group" refers to chemical groups comprising one or
20 more oxygen atoms and carrying a negative charge. Such chemical groups include, but are not limited to, sulfate, phosphate, and carboxyl groups. In some embodiments, the oxyacid group comprise the formula $(XO_n)(O^-)_p$ where X is any atom capable of forming oxyacid groups (*i.e.*, any atom capable of binding three or more oxygen atoms) and p and n are whole
25 numbers.

As used herein, the term "sample" is used in its broadest sense. In one sense it can refer to a materials containing selectin or selectin ligands. In another sense, it is meant to include a specimen or culture obtained from any source, as well as biological and environmental samples. Biological samples may be obtained from animals (including
30 humans) and encompass fluids, solids, tissues, and gases. Biological samples include blood products, such as plasma, serum and the like. Environmental samples include environmental material such as surface matter, soil, water, crystals and industrial samples. These examples are not to be construed as limiting the sample types applicable to the present invention.

DETAILED DESCRIPTION OF THE INVENTION

It is an object of this invention to provide a system for inhibition of the binding of receptors (*e.g.*, selectins) to their counterpart ligands, especially but not limited to the interaction between two cells. For example, the present invention provides lipid compositions and polymerized lipid compositions that display all the features necessary to inhibit selectin binding at nanomolar concentrations when tested in appropriate cell bioassays for ligand binding. Polymerized liposomes and lipid sheets have been proposed in other contexts (Spevak *et al.*, *Adv. Mater* 7:85, 1995; Reichert *et al.*, *J. Am. Chem. Soc.* 117:829, 1995; Charych *et al.*, *Science* 261:585, 1993; Charych *et al.*, *Chem. Biol.* 3:113, 1996). However, the present invention is the first instance where polymerized liposomes have been shown to be effective in a biological system involving the interaction of two eukaryotic cells. This is also the first instance where polymerized liposomes have been shown to be an effective ligand for a binding system with a plurality of separate determinants. Polymerized liposomes with oligosaccharides like sLe^x attached to the surface have been shown to have the ability to inhibit selectin binding (Spevak *et al.*, *J. Med. Chem.* 39:1018, 1996). Furthermore, the present invention is the first instance where polymerized liposomes, having only a negatively charged group (*e.g.*, oxyacid group) on the surface, have substantial ability to inhibit selectin binding, even without attached carbohydrate. The present invention also provides non-polymerized lipid assemblies with carbohydrate and acidic groups that act as a two-component recognition site for inhibiting cell-cell interaction. Surprisingly, neutral lipids (*e.g.*, lactose and maltose) can provide the carbohydrate component in some two-component systems. In some embodiments, the present invention provides compositions that can selectively inhibit specific members of a receptor family (*e.g.*, selectin family of receptors) while not affecting other family members.

In the present invention, lipid compositions are contacted with one of the interacting cells (*i.e.*, one of the cells involved in a cell-cell interaction), or else introduced into an environment where the cells are expected to interact. This type of intervention is of therapeutic interest in any circumstance where the adherence, migration, or activation of cells is mediated by a selectin or similar receptors, and adverse to the well-being of the host.

The polymerized lipid compositions for use in this invention can comprise three elements:

1. A lipid sheet stabilized by covalent crosslinking between a proportion of the lipids.

2. Optionally, a saccharide or similar structure that meets the carbohydrate binding requirement of selectins or other receptors. Typically, the carbohydrate is part of a glycolipid that is one of the crosslinked lipids in the structure, but it may instead be trapped between other lipids that form the crosslinked scaffold.
3. A negatively charged or electronegative group (usually a carboxylic acid or oxyacid) that meets the anionic binding requirement of receptors (e.g., P- and L-selectin; although, surprisingly, in some embodiments, the oxyacid compositions of the presently claimed invention provide inhibition of for E-selectin as well). There is no requirement that the group play exactly the same role as the sulfotyrosines of PSGL-1 in the case of selectins, as long as the anionic binding requirement is satisfied.

The unpolymerized, two-component lipid assemblies of the present invention comprise:

1. A plurality of assembled lipid monomers.
2. A saccharide or similar structure attached to a lipid in the lipid sheet that meets the carbohydrate binding requirement of selectins or other receptors. Typically, the carbohydrate is part of a glycolipid, but it may instead be trapped between other lipids that form the lipid assemblies.
3. A negatively charged or electronegative group (usually a carboxylic acid or oxyacid) that meets the anionic binding requirement of receptors. There is no requirement that the group play exactly the same role as the sulfotyrosines of PSGL-1 in the case of selectins, as long as the anionic binding requirement is satisfied.

When exemplary compositions were prepared and tested for inhibitory activity in a cell bioassay, a number of important observations were made that underscore the improvement provided by this technology.

- Polymerized liposomes have not been tested previously for inhibition of multi-component binding. The relative positioning of the saccharide and the negatively charged group is a chance of random polymerization, not a controlled structure as it is in stepwise chemical synthesis of small molecules. It could not be predicted that an effective orientation would result, but it was

found that active compositions are reproducibly produced without difficulty. New determinant combinations are easily assembled and tested for activity.

- The negatively charged group of the natural selectin ligand PSGL-1 is sulfotyrosine, and the nature of what would be required to satisfy the anionic binding requirement in liposomes was unknown. It was found that the anionic binding requirement does not require the anion to be on a protein or carbohydrate component, but can be directly coupled to lipids that become part of the lipid sheet. Surprisingly, the anionic component need not be a sulfate group, but in some embodiments can be provided as a simple carboxylic acid headgroup on the lipid.
- The presence of the acid group on neighboring lipids unexpectedly reduced the stringency of the oligosaccharide requirement. Neutral disaccharides such as lactose and maltose have not previously been shown to have any selectin binding activity, and were included in the initial experiments as "negative controls." Unexpectedly, compositions containing these sugars and anionic lipids were potent selectin inhibitors. This is of considerable commercial interest, because the manufacture of compositions containing sugars like lactose is easier and less expensive than those containing more complex sugars such as sLe^x.
- The inhibitory activity was remarkably high. In the cell bioassay, the sLe^x analog-anionic lipid combination had an IC₅₀ as low as 2 nM, which is up to 10⁶-fold lower than sLe^x monomer. The lactose anionic lipid combination was effective at 15 nM. This means that an effective therapeutic dose can be prepared at a lower cost and administered in a smaller volume than prior art compositions.
- Surprisingly, cell rolling assays (*See e.g.*, Example 4) demonstrated that liposomes comprising oxyacid groups (*e.g.*, sulfate groups), with and with carbohydrates, were able to inhibit E-selectin-dependent cell adhesion. This is in direct contrast to the teachings of the prior art which teaches that E-selectin binding is not influenced by sulfate groups (*See e.g.*, Pouyani *et al.* and Sako *et al.*, *supra*).

Figure 2 shows exemplary lipid compositions of this invention, in which an analog of sLe^x is displayed on the surface of a polymerized unilamellar liposome. Only the first

structure (*i.e.*, the structure with surface exposed acidic groups) demonstrated inhibitory activity for P-selectin binding in the bioassay, emphasizing the importance of the anionic component in the composition.

5 Because the carbohydrate and anionic determinants can be on separate lipids in the lipid compositions of the present invention, another benefit of the approach described here is that the components can be separately screened and titrated to produce improved compositions with refined binding characteristics.

Liposomes with oxyacid groups in different proportions were prepared as vehicle controls for experiments with liposomes having attached carbohydrate. When tested in a selectin inhibition assay, it was discovered that the presence of the oxyacid was sufficient to impart the liposomes with selectin inhibition capacity.

Previous research on selectins has indicated that the ligand binding specificity depends on a number of structural features present in the oligosaccharide of the natural ligand, sLe^x. These components are the 3-hydroxy group of the fucose subunit and the negatively charged group of the neuraminic acid subunit of sLe^x. In the context of L-selectin binding, the requirements are believed to include the 2-, 3-, and 4-hydroxy groups of the fucose subunit and the negatively charged group of the neuraminic acid subunit. As indicated above, P- and L-selectin also have a requirement for a negatively charged group, which for P-selectin ligands is provided by sulfotyrosine residues on the protein backbone.

20 In view of the current understanding of selectin binding requirements, it is remarkable that polymerized liposomes bearing only negative charged groups (*i.e.*, liposomes without carbohydrates) are such potent inhibitors. Although it is not necessary to understand the mechanism in order to use the present invention, and it is not intended that the present invention be so limited, it is contemplated that the polymerization of the lipids confers a rigidity that facilitates stable complex formation between selectins and the acid head groups.

25 Figure 1 shows two examples of polymerized liposomes of this invention. Compared to carboxylic acid, oxyacids like sulfate and phosphate were substantially more effective in the absence of carbohydrate in providing potent selectin inhibitory capacity. As shown by the data in Example 3 below, the lipids with oxyacid headgroups need be only a proportion of the total lipid in the preparation to be effective.

30 The lipid compositions of the present invention are of interest not only as selectin inhibitors, but also as potential inhibitors of other cell-cell interactions involving a lectin (*i.e.*, carbohydrate binding receptor) system. Interactions involving sulfated oligosaccharides, such

as are found of heparin, other cell-surface mucins like heparan sulfate, gangliosides, and other glycans and glycoproteins all may be capable of inhibition by compounds of this nature. Fine-tuning the particular oxyacid or plurality of oxyacids used, the nature of the non-oxyacid lipids in the composition, and the proportion of each component, is a means to broaden or narrow the focus of the inhibition.

I. Preparation of polymerized lipid compositions

It will be readily appreciated from the drawing in Figure 1 and the data provided in Example 2 that the practice of this invention is not critically dependent on the chemical details of the composition. The practitioner is free to assemble the composition according to a number of different approaches. Variations in polymerization chemistry and the conjugation of determinants are permitted and included in the scope of this invention. Designing particular linkages between an oxyacid and a lipid is well within the skill of the ordinary practitioner. The optimization of the compounds may be achieved by routine adjustment and following the effects of adjustment on selectin binding in one of many assays established in the art.

The following section is provided merely as an illustration of possible approaches for the convenience of the reader.

A. Preparation of Components of the Lipid Composition

The invention uses lipids both to support the determinants required to inhibit receptor (e.g., selectin) binding, and as components for forming the lipid assemblies. Examples of lipids that can be used in the invention are fatty acids, preferably containing from about 8 to 30 carbon atoms in a saturated, monounsaturated, or multiply unsaturated form; acylated derivatives of polyamino, polyhydroxy, or mixed aminohydroxy compounds; glycosylacylglycerols; phospholipids; phosphoglycerides; sphingolipids (including sphingomyelins and glycosphingolipids); steroids such as cholesterol; terpenes; prostaglandins; and non-saponifiable lipids.

In some embodiments, the active negatively charged group of the composition is typically an oxyacid of the form $(XO_n)(O^-)_p$, wherein $n + p > 2$ (although other acidic groups such as carboxyl groups are also contemplated). In this case, the lipid will typically be of the form $R_m(XO_n)(O^-)_p$ wherein each R comprises an aliphatic hydrocarbon (which are not necessarily the same), m is 1 or 2, $(XO_n)(O^-)_p$ is an oxyacid where X is an atom capable of

binding three or more oxygen atoms, and $n + p > 2$. Preferred oxyacids are sulfate and phosphate. A phosphate may be conjugated through one or two of its oxygens to aliphatic hydrocarbons. For any negatively charged component of the composition, any additional features may be present between the acid and the aliphatic or membrane anchoring group. These include spacers such as polyethylene glycols, except where they are in an excessive length so as to negatively impact upon binding and other heteroatom-containing hydrocarbons. The acid group may also be present on a substituent such as an amino acid, a sugar, or a pseudo-sugar, which includes phosphorylated or sulfated forms of cyclohexidine, particularly hexaphosphatidyl inositol and hexasulfatidyl inositol.

In certain embodiments, the oxyacid group is present on an amino acid. In other embodiments, the oxyacid group is present on a sugar (*e.g.*, monosaccharide, disaccharide, oligosaccharide, bridged saccharide, and analogs thereof) or a pseudo-sugar such as cyclohexidine or other ring structures. Of particular interest are phosphorylated or sulfated forms of cyclohexidine, particularly hexaphosphatidyl inositol and hexasulfatidyl inositol (*See e.g.*, Cacconi *et al.*, J. Biol. Chem. 269:15060, 1994).

The negatively charged group may already be present in the lipid monomers of the lipid assemblies, or may be introduced by synthesis. Examples of lipids with negatively charged headgroups include the fatty acids themselves (where the negative charge is provided by a carboxylate group), cardiolipin (phosphate groups), dioleoylphosphatidic acid (phosphate groups), and the 1,4-dihexadecyl ester of sulfosuccinic acid (sulfate group).

Negatively charged lipids not commercially available can be synthesized by standard techniques. A few non-limiting illustrations are provided below. In one approach, fatty acids are activated with N-hydroxysuccinimide (NHS) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDC) in methylene chloride. The leaving group N-hydroxysuccinimide can be displaced with a wide range of nucleophiles. In one example, glycine is used to yield a fatty acid-amino acid conjugate with a negatively charged headgroup. Glutamic acid can be coupled to the activated fatty acid to yield a fatty acid-amino acid conjugate with two negative charges in its headgroup. In another synthetic approach, 2,3-bis((1-oxotetradecyl)oxy)-butanedioic acid is prepared by adding myristoyl chloride in toluene to a pyridine solution of dl-tartaric acid. The clarified solution is concentrated to yield the product, which is recrystallized from hexane (Kunitake *et al.*, Bull. Chem. Soc. Japan, 51:1877, 1978).

A sulfated lipid, the 1,4-dihexadecyl ester of sulfosuccinic acid, is prepared as follows: a mixture of maleic anhydride and hexadecyl alcohol in toluene with a few drops of concentrated sulfuric acid is heated with azeotropic removal of water for 3 hours. The dihexadecyl maleate is recrystallized, then heated with an equimolar amount of NaHSO_3 in water at 100°C for 2-3 hours. The product is recovered by evaporating the water and extracting the lipid into methanol (Kunitake *et al.*, *supra*).

Alkyl sulfonates may be synthesized as follows: a lipid alcohol is obtained (Sigma), or the acid group of a fatty acid is reduced to an alcohol by reacting with lithium aluminum hydride in ether to convert the carboxylate into an alcohol. The alcohol can be converted into a bromide by reaction with triphenylphosphine and carbon tetrabromide in methylene chloride. The bromide is then reacted with bisulfite ion to yield the alkyl sulfonate. Sulfates may be prepared by reacting an activated fatty acid with a sulfate-containing amine. For example, the N-hydroxysuccinimide ester of 10,12-pentacosadiynoic acid is reacted with taurine to yield N-10,12-pentacosadiynoyl taurine. Sulfates may also be prepared by reacting an alcohol (*e.g.*, lauryl alcohol), with sulfur trioxide-trimethylamine complex in anhydrous dimethylformamide for 2.5 hours (Bertozzi *et al.*, *Biochem.* 34:14271, 1995).

Phosphate-containing lipids not commercially obtainable are also readily synthesized. For example, to prepare dialkyl phosphate compounds, phosphoryl chloride is reacted with the corresponding alcohol. To make dihexadecyl phosphate, phosphoryl chloride is refluxed with three equivalents of hexadecyl alcohol in benzene for twenty hours, followed by recrystallization of the product (Kunitake *et al.*, *supra*). Monoalkyl phosphates may be prepared by reacting, for example, 10,12-hexacosadiyne-1-ol (1 equivalent) with phosphoryl chloride (1.5 equivalents) at ambient temperature in dry carbon tetrachloride (CCl_4) for approximately 12 hours, then boiling under reflux for 6 hours. Removal of the solvent and heating the residue with water for 1 hour yields the desired 10,12-hexacosadiyne-1-phosphate (Hupfer *et al.*, *Chem. Phys. Lipids* 33:355, 1983). Alternatively a fatty acid activated with NHS can be reacted with 2-aminoethylphosphate to yield the acylated derivative of aminoethylphosphate.

Carbohydrate components suitable for use with the presently claimed invention include any monosaccharides, disaccharides, and larger oligosaccharides with selectin binding activity when incorporated into a polymerized lipid sheet. Simple disaccharides like lactose and maltose have no selectin binding activity as monomers, but when incorporated into liposomes

with oxyacid groups. acquire substantial activity. Accordingly, the range of suitable carbohydrates extends considerably beyond what is used in other selectin inhibitors.

In some embodiments, the carbohydrate is a disaccharide or neutral saccharide with no detectable binding as an unconjugated monomer. In other embodiments, the carbohydrates have substantial binding in the monomeric form, and are optionally synthesized as a multimeric oligosaccharide, although this is not typically required. Preferred oligosaccharides are sialylated fucooligosaccharides, particularly sLe^x and sLe^a, analogs of sialylated fucooligosaccharides, sulfated fucooligosaccharide, particularly sulfo Le^x, and analogs of sulfated fucooligosaccharide. Disaccharides and larger oligosaccharide may optionally comprise other features or spacer groups of a non-carbohydrate nature between saccharide units.

A "sialylated fucooligosaccharide analog" is a saccharide that contains the minimal structural components of sLe^x involved in selectin binding in a spatially similar orientation to that of sLe^x. These components are the 3-hydroxy group of the fucose subunit and the negatively charged group of the neuraminic acid subunit of sLe^x. In the context of L-selectin binding, preferred analogs include the 2-, 3-, and 4-hydroxy groups of the fucose subunit and the negatively charged group of the neuraminic acid subunit. The fucose and sialic acid components may be linked through a disaccharide spacer as they are in sLe^x, through a hydrocarbon linker (as in the tethered analogs exemplified below), or through a synthetic spacer of appropriate length containing such optional features as cyclic and aromatic groups. Examples of the latter type are listed in the review by Sears *et al.* (Proc. Natl. Acad. Sci. USA 93:12086, 1996) and shown in Figure 8.

Certain analogs and other oligosaccharides of particular interest include the following:

- 1) Tethered disaccharides, containing a spacer between two sugars, particularly sialic acid or a sulfated form thereof and fucose, wherein the spacer is a linear or branched alkyl group (See *e.g.*, Figure 10) or mixed hydrocarbon (Hanessian *et al.*, J. Syn. Lett. 868, 1994);
- 2) Analogs comprising a fucose residue and the carboxylic acid group of sialic acid connected by hydroxylated ring structures (Lin *et al.*, Biorganic Med. Chem. Lett. 6:2755, 1996);
- 3) Lactose sulfated at one or more positions (Bertozzi *et al.*, Biochemistry 34:14271, 1995);
- 4) Neutral disaccharides with an ether linkage to a carboxylic acid group (Hiruma *et al.*, J. Am. Chem. Soc. 118:9265, 1996);
- 5) A monosaccharide (not necessarily fucose) linked through multiple 5- or 6-member ring structures to a carboxylic acid group, at least one of the ring structures being a phenyl group (Dupre *et al.*, Bioorg. Med. Chem. Lett. 6:569, 1996);
- 7)

Glycopeptides, comprising a fucose or similar monosaccharide linked via a plurality of peptide bonds to a carboxylic acid (Cappi *et al.*, Angew. Chem. Int. Ed. Engl., 1996; and Wang *et al.*, Tetrahedron Lett. 37:5427, 1996); 8) Tri- and tetrasaccharides with a plurality of sulfate groups (Nelson *et al.*, Blood 82:3253, 1993); and 9) Phosphorylated or hydroxylated cyclohexanes, particularly hexaphosphatidyl inositol and hexasulfatidyl inositol (Cacconi *et al.*, J. Biol. Chem. 269:15060, 1994).

Many mono and disaccharides are available commercially. The syntheses of more complex carbohydrate structures for selectin binding are described extensively in the art, and need not be elaborated here. Academic articles of interest to the reader may include Tonne *et al.* (Tetrahedron 45:5365, 1989); Drueckhammer *et al.* (Synthesis 499, 1989); Hindsgaul (Sem. Cell Biol. 2:319, 1991); Look *et al.* (Anal. Biochem. 202:215, 1992); Ito *et al.* (Pure Appl. Chem. 65:753, 1993); and DeFrees *et al.* (J. Am. Chem. Soc. 117:66, 1995).

Conjugation of carbohydrates onto lipids can be conducted by any established or devised synthetic strategy, suitably protecting the carbohydrate during conjugation as required. One method is to react a fatty acid activated by N-hydroxysuccinimide with an amino sugar such as glucosamine or galactosamine. If an oligosaccharide-lipid conjugate is desired, the oligosaccharide may be synthesized first, utilizing an amino sugar as one of the subunits. The amino group of the amino sugar is then acylated by the activated fatty acid to yield the lipid-oligosaccharide conjugate. It should be noted that in an oligosaccharide, the amino sugar-fatty acid conjugation may interfere sterically with binding to the desired target. Thus it may be desirable to extend the oligosaccharide by interposition of other sugar subunits between the amino sugar-lipid conjugate, and the portion of the saccharide acting as a ligand. For example, for sLe^x, the amino sugar-fatty acid conjugation may introduce steric hindrance of binding if the amino sugar is too close to the binding moieties of the sLe^x. Thus the sLe^x should be extended by coupling the amino sugar to the GlcNAc subunit of sLe^x via an O-glycosidic bond, instead of substituting the amino sugar for the GlcNAc subunit, in order to avoid steric hindrance of binding.

Another method utilizing the amino group of an amino sugar is to introduce an iodoacetyl group onto the amino group, followed by reaction of the amino group with a thiol-containing compound (*e.g.*, cystamine and cysteine) that contains additional functional groups for further derivatization.

O-glycosides are readily formed by the acid-catalyzed condensation of an alcohol with monosaccharides such as glucose or mannose. N-Fmoc-ethanolamine can be added to the

reducing end of glucose, followed by deprotection of the amino group with piperidine. The free amino group of the compound can then be acylated with an activated fatty acid to form a carbohydrate-lipid conjugate. Alternatively, glycosyl halides (formed by reacting a sugar with a haloacid such as HCl) can be used, where nucleophilic displacement of the halide by an alcohol forms the O-glycoside.

Another method involves the formation of N-glycosides by reacting an amine with a reducing sugar. This reaction is readily accomplished by reacting the sugar (*e.g.*, glucose) with an amine (*e.g.*, decylamine) at ambient temperature for approximately 48 hours. Alternatively, heating the sugar with amine (*e.g.*, stearylamine in 2-3 molar excess) at 80°C in an ethanol/water solution will suffice to form the N-stearyl glycoside (Lockhoff, *Angew. Chem. Int. Ed. Eng.* 30:1161, 1991). In order to increase the stability of the N-glycoside, the product is peracetylated by stirring in 60% pyridine/40% acetic anhydride at 0°C. The peracetylated product is then dissolved in anhydrous methanol. 1M sodium methoxide is added to adjust the pH to approximately 10, and the mixture stirred at room temperature for 3 hours to yield the N-acetyl-N-glycoside.

An extension of this method of introducing additional functionality via N-glycosides involves the addition of a polyfunctional amine to the sugar. For example, N-allylamine can be added to a saccharide with a free reducing end, followed by reaction of the allyl group to provide a suitable point of attachment for a fatty acid. One of skill in the art will recognize that the sugar conjugates depicted in Figure 4 are created by reacting N-allylamine with sLe^x analog, followed by peracetylation of the N-glycoside. The hydroxyl groups can be deprotected with a catalytic amount of sodium methoxide, resulting in the N-acetylated N-allyl glycoside. Alternatively, the amino group of the N-allyl glycoside can be directly acetylated with an acid chloride (Lockhoff, *Angew. Chem. Int. Ed. Eng.* 30:1161, 1991). A mercaptoamine such as cystamine can then be added to the N-allyl glycoside by irradiation with UV light (Roy *et al.*, *J. Chem. Soc. Chem. Comm.* 1059, 1988), which results in an N-glycoside with a free amino group. The free amino group can then be readily coupled to an activated fatty acid such as the N-hydroxysuccinimide ester of 10,12-pentacosadiynoic acid to yield the conjugated sugar.

Other methods of attaching fatty acids or other lipids to carbohydrates can be accomplished by forming suitable thioglycosides or C-glycosides. These compounds can then be further derivatized in a manner analogous to the methods used for the N-glycosides. The C-allyl glycoside of neuraminic acid, for example, is readily formed by reaction of N-acetyl

mannosamine and sodium pyruvate in the presence of NeuAc aldolase as a catalyst to yield N-acetyl neuraminic acid. Treatment of the crude reaction mixture with HCl gas in ethanol yields an ethyl ester; this is followed by reaction with acetyl chloride to give a glycosyl chloride (this step also results in acetylation of the hydroxyl groups). Reaction of this
5 glycosyl chloride with allyl tributyltin and a catalytic amount of bis (tributyltin) under UV irradiation (e.g., a 450 Watt Hanovia lamp, equipped with a Pyrex filter) yields a C-allyl glycoside; the acetyl groups are then removed from the hydroxyl groups with sodium ethoxide in ethanol. This yields the ethyl ester of the C-allyl glycoside of neuraminic acid (Nagy *et al.*, Tetrahedron Letters 32:3953, 1991).

10 In a manner analogous to the reaction scheme described above for the N-allyl glycosides, the C-allyl glycoside of a sugar may be reacted with cystamine, resulting in the addition of the thiol group to the allyl group, followed by reaction of the amino group with an activated fatty acid.

Conjugation of a carbohydrate to a lipid via an amide bond may be accomplished if
15 the carbohydrate has a free carboxyl group. Mixing the carbohydrate and 2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)-ethanamine and activating the carboxyl group by using 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDC) and 1-hydroxybenzotriazole (HOBt) in methylene chloride, followed by reduction of the azido group to an amine with $H_2/Pd(OH)_2/C$ in ethanol/water/dioxane/acetic acid (2:1:2:1), yields an amine-derivatized carbohydrate that
20 can then be linked to a fatty acid by a variety of activating chemistries (Lin *et al.*, Bioorg. & Med. Chem. Lett. 6:2755, 1996).

Carbohydrates can also be conjugated to lipids using enzymatic methods. Sugars may be transphosphatidylated by reacting diacylphosphatidyl choline and the sugar in the presence of phospholipase D, resulting in the diacylphosphatidyl-sugar (Wang *et al.*, J. Am. Chem.
25 Soc. 115:10487, 1993).

B. Assembly of the Lipid Composition

Appropriately derivitized lipids (*i.e.*, lipids modified with desired chemical groups such as oxyacid groups and carbohydrates) are combined, formed into a suitable composition,
30 and optionally cross-linked.

Where appropriate, the combination step includes mixing lipids having the oxyacid with any other lipids that may be included. For polymerized lipid assemblies, the additional lipids may have a carbohydrate, or they may be scaffold lipids that participate in crosslinking

but have no binding determinant, or they may be filler lipids that do not have crosslinking groups. Non-crosslinked (*i.e.*, unpolymerized) lipids may bear either the oxyacid determinant and become stabilized in the composition by entrapment between other crosslinked lipids.

5 The lipids are then formed into a lipid composition. Although the lipid compositions are most typically liposomes, any other arrangement can be used providing it is deliverable to the intended site of action, and displays the determinants needed for selectin binding. The participating lipids are crosslinked members of a lipid sheet, but the lipid sheet need not be part of a lipid bilayer. Micelles and microdroplets are examples of alternative particulate forms suitable for displaying the binding determinants. A single lipid sheet may also be
10 formed about a hydrophobic core of a suitable aliphatic compound. Lipid can also be seeded as a single sheet or bilayer about another core substance, such as a protein complex.

In some embodiments, the lipid compositions may comprise dendrimers (Dendritech, Inc., Midland, MI). Dendrimers can act as designed carriers for organic, inorganic, and biological materials. These compositions are based on an ethylene diamine core, an
15 amidoamine repeat branching structure, and a terminal primary amine surface, and are described in U.S. Patents 5,714,166, 5,527,524, and 5,362,843. Unlike classical polymers, dendrimers have a high degree of molecular uniformity, narrow molecular weight distribution, specific size and shape characteristics, and a highly functional terminal surface. The branching units emanating from the core are highly structured, and the polymer terminates in
20 a radially templated surface with a high number of accessible reactive groups. The present invention contemplates dendrimers that have terminal groups providing ligand binding sites for selectins and other receptors such that the derivated dendrimers provide compositions for inhibiting cell-cell interactions. Any descriptions in this disclosure that refer to liposomes also apply to other types of lipid compositions, unless required otherwise.

25 In preferred embodiments liposomes are used because of their ease of manufacture. A number of methods are available in the art for preparing liposomes. The reader is referred to Gregoriadis (ed): "Liposome technology 2nd ed. Vol I Liposome preparation and related techniques," CRC Press, Boca Raton, 1993; Watwe *et al.* (Curr. Sci. 68:715, 1995); Vemuri *et al.* (Pharm. Acta Helvetiae 70:95, 1995); and U.S. Patents 4,737,323, 5,008,050, and
30 5,252,348. Frequently used techniques include hydration of a lipid film, injection, sonication, and detergent dialysis. When using diyne chemistry and single-chain fatty acids for crosslinking, a preferred method is sonication (Hub *et al.*, Angew. Chem. Int. Ed. Engl. 19:938, 1980) or extrusion. This extrusion method is easy to use and produces unilamellar

spherical vesicles of small and uniform size. Briefly, a thin film of lipid is heated with water above 90°C. and then cooled to about 4°C, which is below the crystallization temperature (T_c) (Lopez *et al.*, Biochem. Biophys. Acta 693:437, 1982) to permit the lipids to form a "solid analogous" state. The mixture is then sonicated for several minutes, with longer times (*i.e.*, approximately 15 minutes) typically producing more uniform vesicles.

After formation, the vesicles may be reduced in size, if desired, by freeze-thaw cycles or extruding through filters of progressively smaller pore size. Vesicles of any diameter are included within the scope of this invention, but they are preferably less than about 400 nm in median diameter, and more preferably less than about 200 nm in diameter. Smaller sized vesicles can be sterile-filtered and are less susceptible to uptake by phagocytic cells.

The lipids used in any of these compositions will have been prepared with functional groups that can be covalently crosslinked once the lipid sheet is formed.

Several approaches are known in the art for covalently crosslinking lipids.

Polymerization may be accomplished by irradiation with ultraviolet light, or by radical initiation with compounds such as hydrogen or benzoyl peroxide, as appropriate, or lipid diynes, styrene-containing lipids, acrylic-containing lipids, and lipid dienes; polymerization (by forming amide bonds) of lipids containing free (unprotected) amino and carboxyl groups; and polymerization (by oxidation of thiol groups) of thiol-containing lipids (wherein each lipid must contain at least two thiol groups in order to be crosslinked). Azides, epoxides, isocyanates and isothiocyanates, and benzophenones also afford methods of crosslinking lipids (See *e.g.*, Wong, S.S., *Chemistry of Protein Conjugation and Cross-Linking*, Boston: CRC Press, 1993; and Hermanson, G.T., *Bioconjugate Techniques*, San Diego: Academic Press, 1996).

An example of polymerization of lipids by forming amide bonds is the polymerization of N- ϵ -palmitoyl-L-lysine-N- β -(2-acetylamino-2-deoxy- β -glucopyranosyl)-L-asparagine by carbodiimides. The carbohydrate, lipid-modified dipeptide is readily assembled by standard solid phase peptide synthesis methods using commercially available N- α -Fmoc-N- β -(3,4,6-tri-O-acetyl-2-(acetylamino)-2-deoxy- β -glucopyranosyl)-L-asparagine (from Novabiochem) and N- α -Fmoc-N- ϵ -palmitoyl-L-lysine (which is readily synthesized by coupling palmitic acid activated with N-hydroxysuccinimide to the free ϵ -amino of commercially available N- α -Fmoc-L-lysine). Removal of the modified dipeptide from the solid-phase resin and deprotection of the functional groups is carried out by standard methods. The carbohydrate, lipid-modified dipeptide can be co-polymerized with a second dipeptide, N- ϵ -palmitoyl-L-

lysine-L-aspartic acid. in order to provide a liposome with both carbohydrate-bearing and negatively-charged groups on its surface.

An example of polymerization of lipids by oxidation of thiol groups is as follows: 10-undecenoic acid (10-undecylenic acid) is brominated by addition of HBr by Markonikov addition across the double bond, resulting in 10-bromoundecanoic acid (Streitweiser *et al.*, Introduction to Organic Chemistry, New York: Macmillan, 1976, pp. 278-285); 10-thioundecanoic acid is prepared by treatment of 10-bromoundecanoic acid with thiourea in ethanol and subsequent hydrolysis by aqueous NaOH (Streitweiser *et al.*, Introduction to Organic Chemistry, New York: Macmillan, 1976, pp. 242-243). The thiol is then protected with the trityl group by heating with triphenylmethanol and boron trifluoride etherate in glacial acetic acid, followed by workup with ethanol, water, and powdered sodium acetate (Bodanszky *et al.*, *The Practice of Peptide Synthesis*, New York Springer-Verlag, 1984, p. 83). The protected thiol fatty acid is then activated with N-hydroxysuccinimide and reacted with S-trityl-L-cysteine (Novabiochem). The fatty acid-amino acid conjugate is then treated with trifluoroacetic acid to remove the trityl groups, resulting in N-(10'-thioundecanoyl)-cysteine. The dithiol can then be polymerized by oxidation with molecular oxygen.

Additional examples of lipids that can be crosslinked are reviewed in Ringsdorf *et al.*, Angew. Chemie Int. Ed. Eng., 27:113-158, 1988, and references therein, and Johnston *et al.*, "Polymerized Liposomes and Vesicles," Chapter 9 in Liposome Technology, Vol. 1 (G. Gregoriadis, Ed.), Boca Raton, Florida: CRC Press, 1984, pp. 123-129 and references therein.

A preferred method of polymerizing lipids is by polymerization of lipid diynes such as 10,12-pentacosadiynoic acid (Farchan Laboratories, Gainesville, FL) by ultraviolet light. Polymerization reactions of diacetylenic compounds have been extensively studied and have been utilized in the formation of polymerized liposomes, micelles, and other supramolecular assemblies (See e.g., Frankel *et al.*, J. Am. Chem. Soc. 113:7436, 1991; Furhop *et al.*, J. Am. Chem. Soc. 113:7437-7439, 1991; and Spevak *et al.*, Advanced Materials 7:85, 1995). Diynes are convenient because they are easily polymerized using UV light, obviating the need for a radical initiator. In addition, the polymerized lipid is colored and the degree of polymerization can be easily monitored.

An example of the preparation of a crosslinkable diacyl lipid, 1,2,3-triamino-(bis-N1,N3-pentacos-10, 12-diynoyl) propane, is as follows. The t-butyloxycarbonyl (Boc) group is used to protect the amino group of 2-amino-1,3-propanediol. The diol is converted into a

di-mesylate with mesyl chloride, followed by immediate reaction with tetrabutylammonium azide in DMF. The azide groups are converted to amines by reaction with PtO_2/H_2 . The compound is then reacted with the N-hydroxysuccinimide derivative of 10,12-pentacosadiynoic acid. Finally, the Boc group is removed with trifluoroacetic acid to yield the 1N,3N-bis (10,12-pentacosadiynoyl)-1,2,3-triamonopropane.

The lipids of the composition are crosslinked by activation appropriate to the type of polymerization chemistry employed. Diyne lipids are cross-linked by UV irradiation as originally described (Hub *et al.*, *supra*), monitoring visible absorption to follow the course of the reaction, which is usually complete within 20-60 minutes. Free radical initiators, when used, are removed from the preparation after polymerization by a suitable technique, such as dialysis.

II. Features of the lipid compositions

One of the benefits of the compositions is the ease by which different substituents can be screened and titrated for selectin binding. The optimal proportion of a particular oxyacid with respect to other lipids in the preparation are determined empirically by titrating each substituent into the compositions and conducting a suitable selectin activity assay. This approach is illustrated further in Examples 2 and 3.

The proportion of lipids bearing an oxyacid varies depending on the binding characteristics of the preparation. In general, higher proportions of oxyacids will be more potent inhibitors of receptors (*e.g.*, selectins) up to some undetermined point, but may be less specific. Excessive proportion of sulfate or phosphate may confer the composition with inhibitory activity for other biological reactions, particularly those that are naturally inhibited by highly charged molecules, such as heparin. Where this is an issue, the proportion of such acids may be titrated down to a range of about 1% to 50%, or 1% to 10%, or 0.5% to 2%, as appropriate. In other embodiments, the proportion of oxyacid is maximized to between 10% and 100%, or 25% to 100, or 50% to 100% , or 75% to 100%. In other embodiments, the proportion of oxyacid is between 35% and 75%, or between 40% and 60% of the total lipid in the preparation.

Another variable is the nature of lipids not bearing oxyacid groups. Frequently used lipids have headgroups such as hydroxyl groups, alkyl groups, amino groups, and the like. These groups can be mixed and matched as desired to convey additional binding characteristics.

For polymerized lipid assemblies, the degree of polymerization between lipids in the lipid sheet is a factor of the proportion of lipids having crosslinkable substituents, and the completeness of the polymerization reaction. The practitioner can limit the amount of polymerization by including lipids in the preparation that will not participate in crosslinking.

5 Although it is not necessary to understand the mechanism in order to use the present invention, and it is not intended that the present invention be so limited, it is contemplated that the synergy between the carbohydrate and anionic components is imparted partly by the rigidity of the polymerized lipid structure. It is recommended that at least 25%, preferably 50%, more preferably 75%, still more preferably 90%, even more preferably 95%, and still
10 more preferably almost 100% of the lipids in the sheet are crosslinked. The entire sheet may be polymerized into one unit, or into separate patches or tiles.

Where a proportion of non-reactive lipid is included as filler to reduce the degree of crosslinking, the oxyacid determinant is typically on the crosslinked lipid rather than the filler lipid. However, the opposite arrangement is possible, insofar as the filler lipid will become
15 entrapped by the neighboring crosslinks. Thus, in certain embodiments of the invention, the oxyacid lipid is a non-crosslinked lipid present in a lipid sheet comprising other lipids that are crosslinked. This approach is especially appropriate when using glycosphingolipids to satisfy the carbohydrate determinant. Preferred lipids of this type are sulfoglucuronyl glycosphingolipids (Needham *et al.*, Proc. Natl. Acad. Sci. USA 90:1359, 1993).

20 Both carbohydrate groups and electronegative groups are optionally conjugated to the lipids through a spacer group. As will already be appreciated from the synthetic methods described earlier, hydrocarbon spacers of about 2 carbons in length provide a convenient approach to conjugation. In certain embodiments, the spacer groups are polyethylene glycols that improve the stealth of the liposomes from uptake by reticuloendothelial cells. Since the
25 anionic group and the carbohydrate group must work in concert, the length of the spacer arms should match. The potency of polymerized lipid compositions is believed to derive in part from the structural rigidity, and many embodiments have spacers of minimal length.

In certain embodiments of this invention, a proportion of the lipids in the lipid sheet have a first attached saccharide, and a separate proportion of the lipids have a second attached
30 saccharide that is different from the first. The two glycolipids are preferably part of the cross-linked structure. Embodiments where there is a higher plurality of different independently conjugated saccharides are contemplated. Any combination of lipids in this arrangement that fulfills the carbohydrate binding requirement of selectins is suitable. In one

example, the first attached carbohydrate is an acidic monosaccharide such as sialic acid or similar sugar and the second carbohydrate is fucose or similar sugar. Combinations of lipids conjugated with different monosaccharides or disaccharides or their analogs are of commercial interest because of their ease of synthesis.

5 The oxyacid group can be conjugated to the lipid through an optional spacer group. As will already be appreciated from the synthetic methods described earlier, hydrocarbon spacers of about 2 carbons in length provide a convenient approach to conjugation. In certain embodiments, the spacer groups are polyethylene glycols that improve the stealth of the liposomes from uptake by reticuloendothelial cells. The potency of polymerized lipid compositions is believed to derive in part from the structural rigidity, and many embodiments have spacers of minimal length.

10 The lipid assemblies of the present invention can be classified on the basis of their potency in various test assays known in the art. For example, when tested for inhibition of the binding of isolated selectin to cells expressing a selectin ligand such as PSGL-1, the liposomes preferably are able to inhibit the binding in a manner that attains 50% maximal inhibition (IC_{50}) at a concentration of no more than 100 μ M, preferably no more than about 10 μ M, still more preferably no more than about 1 μ M, even more preferably no more than about 100 nM, and still more preferably no more than about 10 nM in terms of total lipid. A preferred binding assay of this type uses HL-60 cells, and is illustrated in Example 2.

20 The lipid assemblies may also be categorized in any assay on the basis of the relative IC_{50} compared with a suitable standard. The standard may be an oligosaccharide presented uncomplexed to liposomes or in a monomeric form, such as sLe^x or sLe^x analog. The standard may also be a liposome having no oligosaccharide but otherwise the same lipid composition, or a liposome made with 100% carboxy terminated or hydroxy terminated lipids.

25 In certain embodiments, the polymerized liposomes have an IC_{50} that is preferably 10^2 -fold lower, more preferably about 10^3 -fold lower, more preferably about 10^4 -fold lower, still more preferably about 10^5 -fold lower, and even more preferably about 10^6 -fold lower than that of the standard.

30 Several types of units can be used to refer to the concentration of liposomes. Where liposomes comprise carbohydrates, the concentration may be referred to as carbohydrate monomer equivalents. Translation into the equivalent lipid concentration is an easy calculation based on the molecular mass of carbohydrate and lipid used and the proportion of lipid comprising carbohydrate. Translation from lipid or carbohydrate concentration to the

number of liposomes particles per unit volume can be performed knowing the average diameter or particles. The concentration units recited in this disclosure can be converted where necessary for comparison.

This invention also includes embodiments that are selective for P- and L-selectin in comparison with E-selectin, selective for P- or L-selectin alone, in comparison with the other two selectins, and selective for P-selectin over E-selectin. A lipid assembly is selective if it has an IC_{50} in an assay for inhibiting one selectin that is higher than its IC_{50} in an assay for inhibiting another selectin. An assay is preferably used for this determination that allows the particular selectin to be the only variable. The HL-60 selectin binding assay outlined in Example 1 can be used for comparing P- and E-selectin inhibition using the same cells and switching chimeras. Example 4 describes a cell rolling inhibition assay that demonstrates inhibition of P- and E- selectins and selective inhibition of P-selectins over E-selectins. In a similar fashion, the plated mucin in the ELISA described in Example 3 binds a chimera of any of the three selectins, and can be used to compare the inhibitory capacity of a particular composition for all three selectins. Selective inhibitors preferably have an IC_{50} that is about 5-fold higher for the target selectin in comparison with another selectin; more preferably it is 25-fold higher; still more preferably it is 100-fold higher.

Example 3 provides illustrations of selective polymerized liposomes. Non-sulfated sugars like sLe^x and the neutral disaccharides lactose and maltose are selective for L- and P-selectin when presented in the context of carboxy-terminated lipids. sLe^x is also selective in the context of hydroxyl-terminated lipids. Liposomes with sulfate groups either on sulfo Le^x or on a lipid in combination with sLe^x were not selective.

Also included are embodiments that are designed to optimize binding to multiple selectins. These compositions may have a plurality of different carbohydrates and a plurality of different anionic or electronegative groups on separate lipids.

III. Testing of the Polymerized Lipid Compositions

A. *In vitro* Testing and Optimization of the Composition

Assays for determining the ability of a lipid composition to display selectin ligands can be classified as either direct binding assays or inhibition assays.

Direct binding assays are conducted by permitting the composition to interact directly with either a selectin or with a cell expressing a selectin. A lipid sheet containing various test

selectin binding determinants can be polymerized directly onto a microscope slide (Spevak *et al.*, Adv. Mater. 7:85, 1995) and titrated with selectin, or conversely the selectin can be coated onto microtiter plate wells and titrated with labeled lipid particles. Lipid assemblies can also be tested for direct binding to cells expressing selectin ligands, such as HL-60 cells.

5 Since most of the applications for liposomes according to this invention relate to an inhibition of binding between selectin ligand-receptor pairs, it is more usual to develop and test compositions in inhibition assays.

Inhibition capacity can be tested in cell-free assays where one member of the selectin ligand-receptor pair is coupled to a solid surface, and the second is presented for binding in the presence of the potential inhibitor. After washing, the amount of bound second member is quantitated by way of a preattached or subsequently attached labeling system. This type of assay is convenient for comparative screening of a number of different lipid compositions, for example, displaying different carbohydrate and anionic determinants.

10 Many of the current cell-free selectin assay systems make use of selectin chimeras, in which an N-terminal portion of the selectin comprising the binding domain is fused to a second protein fragment that can be used as an attachment means for a labeling system. A frequently used second fragment is an IgG Fc region, which can then be detected using a conjugate made with Protein A or anti-Fc. The construction of chimeras and related assays are described by Watson *et al.* (J. Cell Biol. 115:235, 1992), Aruffo *et al.* (Cell 67:35, 1991), and Foxall *et al.* (J. Cell Biol. 117:895, 1992).

20 One illustration of a convenient cell-free assay is the L-selectin ELISA described in Bertozzi *et al.* (Biochemistry 34:14275, 1995). Briefly, a crude preparation of GlyCAM-1 is obtained from mouse serum. Microtiter plates are coated with polyclonal antibody specific for the peptide backbone of the mucin, overlaid with the mucin, and then washed. A chimera of L-selectin fused to Fc is complexed with biotinylated F(ab')₂ anti-Fc, which in turn is complexed to streptavidin-alkaline phosphatase conjugate. The combined conjugate is preincubated with the potential inhibitor for 30 minutes, then transferred to the microtiter plate wells. After 30 minutes at room temperature, the wells are washed, and developed with the enzyme substrate. In a variation of this type of assay, selectin ligand substitutes such as sulfatides are used that can be coated directly onto the plate. In another variation, the solid substrate is also a polymerized lipid (Spevak *et al.*, Adv. Mater. 7:85, 1995) expressing determinants that are at least as potent for selectin binding as the compositions being tested as inhibitors.

25

30

Beyond the initial screening stage, one- or two-cell bioassays are preferably used during the development of compositions as being more representative of inhibition in a biological system.

A convenient one-cell assay for P-selectin inhibitors makes use of HL-60 cells, available from the ATCC. HL-60 cells naturally express the PSGL-1 antigen at about 36,000 sites per cell (Ushiyama *et al.*, J. Biol. Chem. 268:15229, 1993). The assay is described in Brandlet *et al.* (Glycobiol. 3:633, 1993). Briefly, an E or P-selectin chimera is incubated with biotinylated goat F(ab'), anti-human IgG Fc, and an alkaline phosphatase-streptavidin conjugate for 30 minutes. This complex is then incubated with potential inhibitors for approximately 45 minutes at 37°C. Fifty microliters of the mixture is then added to each well of round-bottom microtiter plates previously blocked with BSA. An equal volume of an HL-60 cell suspension is added and the plate is incubated for 45 minutes at 4°C. Cells are pelleted to the well bottoms by centrifugation, washed, and developed using p-nitrophenyl phosphate.

Other one-cell assays are done with cell isolates rather than cell lines. The ability to inhibit neutrophil adhesion to purified P-selectin immobilized on plastic wells can be determined using the assay described by Geng *et al.* (Nature 343:757, 1990). Briefly, human neutrophils are isolated from heparinized whole blood by density gradient centrifugation on Mono-Poly™ resolving media (Flow Laboratories), and suspended in Hanks' balanced salt solution containing Ca²⁺, Mg²⁺, and human serum albumin (HBSS/HSA). P-selectin is obtained by recombinant expression or is isolated from outdated human platelet lysates by immunoaffinity chromatography on antibody S12-Sepharose™ and ion-exchange chromatography on a Mono-Q™ column (U.S. Patent 5,464,935). The P-selectin is coated onto microtiter plate wells at 5 µg/mL. Cells are added at approximately 2 x 10⁵ per well, incubated at 22°C for 20 min. The wells are then filled with HBSS/HSA, sealed with acetate tape, and centrifuged. After discarding nonadherent cells and supernates, the contents of each well are solubilized with 0.5% hexadecyltrimethylammonium bromide in phosphate buffer and assayed for myeloperoxidase activity (Ley *et al.*, Blood 73:1324, 1989).

Two-cell adherence assays are conducted by testing the ability of a composition to interfere with the attachment of one cell having a selectin to another cell having a ligand for the selectin. One illustration uses COS cells transfected to express the appropriate selectin (See e.g., Aruffo *et al.*, Proc. Natl. Acad. Sci. USA 84:8573, 1987). Transfected cell clones are selected for their ability to support HL-60 cell adhesion. The clones are then expanded

and grown in small-well culture plates as a substrate for the assay. Another suitable substrate cell are human umbilical vein endothelial cells (HUVEC), obtainable from Cell Systems, Inc., and stimulated with 100 U/mL IL-1 β for 4 hours (Martens *et al.*, J. Biol. Chem. 270:21129, 1995). HL-60 cells are labeled by incorporation of 1 μ Ci/mL [3 H]thymidine or 10 μ g/mL calcein. The putative inhibitor is preincubated with the labeled HL-60 cells, presented to the
5 substrate cells, and then the wells are washed and counted.

Lymphocyte adherence can be determined using the frozen section assay originally described by Stamper *et al.* (J. Exp. Med. 144:828, 1976), since modified by Stoolman *et al.* (J. Cell Biol. 96:722, 1988), Arbones *et al.* (Immunity 1:247, 1994), and Brandley *et al.*
10 (*supra*). Briefly, lymphocytes from mouse mesenteric lymph nodes or splenocytes are fluorescently labeled with CMFDA, and incubated with the test inhibitor for approximately 30 minutes at 0°C. The lymphocyte suspension is then overlaid on 10 μ m frozen sections of mesenteric or peripheral lymph nodes ($\sim 3 \times 10^4$ cells/section) and incubated on ice for 30 minutes on a rotator. The suspension is then gently drained from the slide, and the sections
15 are fixed with 3% glutaraldehyde and counterstained with acridine orange. Fucoidan can be used as a positive control for inhibition. The adherence observed in this assay is attributable to L-selectin binding.

Leukocyte flow (rolling cell) assays are also described in Martens *et al.* (*supra*). Neutrophils are isolated from venous blood by dextran sedimentation and Ficoll-HypaqueTM
20 centrifugation. HUVEC are harvested by collagenase treatment, plated onto 0.1% gelatin coated flasks, and cultured. A HUVEC monolayer is mounted on the flow chamber, and perfused for 2 minutes with buffer containing calcium and glucose. The isolated neutrophils are preincubated with the test inhibitor in the same buffer. The neutrophil suspension is then passed over the HUVEC monolayer at a wall shear stress of approximately 1.85 dyne/cm².
25 Interaction is videotaped for about 10-20 minutes using a phase contrast microscope, and an imaging software program (Montana Immunotech, Inc., Bozeman, MT) is used to determine the average number of neutrophils rolling on the monolayer in several different fields of view.

Rolling cell inhibition was observed with oxyacid containing liposomes as demonstrated by human *in vitro* leukocyte-endothelium selectin rolling assays. Shear flow
30 examinations of the liposome constructs by *in situ* video microscopy assays were conducted by observing the inhibition of rolling of cells on an adherent layer of cells. The systems used included, neutrophil-IL-1 β activated HUVEC rolling adhesion; neutrophil-thrombin activated platelet rolling; E-selecting transfectant-neutrophil rolling; as well as neutrophil-neutrophil

rolling. The effects of test compounds on cell interactions were recorded on video tape and quantified by computer image analysis methods.

Glycoliposomes comprising 5% sLe^x analog (*i.e.*, carbohydrate), 50% sulfate-terminated lipid (*i.e.*, oxyacid), and 45% hydroxy terminated lipid were tested in a flow adhesion assay as described above and in Example 4. This type of assay presents a more realistic measure of an inhibitor's ability to block cell adhesion under physiological flow conditions rather than under static adhesion conditions. The E-selectin/L-selectin-dependent adhesion of IL-1 β activated HUVECs and human neutrophils was blocked nearly 100% by as little as 1 μ M of the liposomes as shown in Figure 11(A). This level of inhibition is unprecedented at such a low concentrations of inhibitor. Rolling of neutrophils on E-selectin transfections provided an equally effective test of liposome blocking activity where the liposomes blocker greater than 90% at a 10 μ M concentration as shown in Figure 11(B). Other selectin rolling systems were even more profoundly disrupted. Examining neutrophil rolling on thrombin activated platelets revealed that as little as 0.1 μ M of the liposomes could block 90% of neutrophil-platelet rolling and at 10 μ M blocked nearly 100% as shown in Figure 11(C). Although not as dramatic as for other selectin mediated interactions, the liposomes also blocked 80% of L-selectin-dependent neutrophil-neutrophil rolling as shown in Figure 11(D). Together these results demonstrate a high specific activity for the sulfated-carbohydrate liposomes to inhibit dynamic shear-flow induced selectin-ligand adhesion of leukocytes and endothelial cells.

Rolling experiments also demonstrated the ability to differentially inhibit rolling of leukocytes on endothelial cells (E-selectin) and platelets (P-selectin). Experimental data from both human HUVEC and platelet-leukocyte rolling experiments show that sulfated liposomes bearing sialyl Lewis X-like carbohydrates efficiently block both E- and P-selectin adhesion at shear forces of 1.8 dynes/cm². Figure 12 shows the effect of sLe^x analog and sLe^x-like groups on activated endothelial neutrophil adhesion in rolling cell assays. Figure 13 shows the effect of sLe^x analog and sLe^x-like groups on activated platelet leukocyte adhesion. The dark diamonds with the broken line designate control samples where only buffer was injected into the assay system; the shaded boxes are from sulfated liposomes comprising lactose; the open boxes are sulfated liposomes with no carbohydrate constituent; the open circles are liposomes comprising 3-acetic acid-derived Lewis X carbohydrate; open triangles are liposomes comprising 3-sulfo-derived Lewis X carbohydrate; and open diamonds are sLe^x-derived liposomes. All treatments were 10 μ M solutions.

Surprisingly, the data also show that switching of the sialyl Lewis X-like carbohydrate for lactose as part of the sulfated liposome construct results in complete blocking of platelet-leukocyte adhesion while not further augmenting blocking of HUVEC-leukocyte adhesion. This demonstrates that liposomes constructed to express certain combinations of sulfated lipid and carbohydrates in various combinations may be used to differentially inhibit E-and P-selectin. This unique property can allow treatment of P-selectin associated diseases while leaving intact cellular recruitment and immunity associated with E-selectin adhesion. Since many acute inflammatory diseases are initiated by P-selectin mediated recruitment and more chronic recruitment is associated with E-selectin blocking, liposome therapy differentiating P- and E-selectin would be an excellent pharmaceutical product approach for acute phase inflammatory diseases (*See e.g.*, Biochim. et Biophys. Acta 1197, 215 [1994]).

Also surprisingly, the liposomes with sulfated lipids, both alone and in combination with a carbohydrate group, were able to effectively inhibit cell adhesion resulting from E-selectin binding. Previous studies had indicated that E-selectin binding is not influenced by sulfate groups (*See e.g.*, Pouyani *et al.* and Sako *et al.*, *supra*). Thus the various methods and compositions of the presently claimed invention find use in the inhibition of all selectin types and allow for the selective inhibition of certain selectins over others.

B. *In vivo* testing

Animal models for various diseases with an inflammatory or immunological etiology are known in the art and may be brought to bear in the testing of any composition that shows promising selectin inhibitory action. In models of hyperacute disease such as reperfusion injury, the composition is typically administered within minutes or hours of the inducing event to simulate a clinical setting. In models of chronic disease, the composition is typically administered at regular periods of a week or more during the progression phase. The animal is evaluated by cellular and clinical criteria for the ability of the composition to palliate the condition.

Amongst models suitable for the testing of selectin inhibitors are the following: the cardiac ischemia reperfusion models of Weyrich *et al.* (J. Clin. Invest. 91:2620. 1993), Murohara *et al.* (Cardiovasc. Res. 30:965, 1995), Ma *et al.* (Circulation 88:649. 1993), Tojo *et al.* (Glycobiology 6:463, 1996), and Garcia-Criado *et al.* (J. Am. Coll. Surg. 181:327, 1995); the cardiac infarct model of Silver *et al.* (Circulation 92:492. 1995); the pulmonary ischemia reperfusion models of Steinberg *et al.* (J. Heart Lung Transplant 13:306. 1994) and

Kapelanski *et al.* (J. Heart Lung Transplant 12:294, 1993); the cobra venom acute lung injury model and immune complex lung inflammation model in U.S. Patent 5,486,536; the hemorrhagic shock model of Kushimoto *et al.* (Thrombosis Res. 82:97, 1996); the peritoneal exudate and endotoxin-induced uveitis models of WO 96/35418; the bacterial peritonitis model of Sharar *et al.* (J. Immunol. 151:4982, 1993); the meningitis model of Tang *et al.* (J. Clin. Invest. 97:2485, 1996); the colitis model of Meenan *et al.* (Scand. J. Gastroenterol. 31:786, 1996); the Dacron graft experimental thrombus model of Palabrica *et al.* (Nature 359:848, 1992); the tumor metastasis model of WO 96/34609; the allergic asthma model of WO 96/35418; the allergen mediated pulmonary hypersensitivity model of Gundel *et al.* (Am. Rev. Respir. Dis. 146:369, 1992); the diabetes models of Martin *et al.* (J. Autoimmunity 9:637, 1996) and Yang *et al.* (Proc. Natl. Acad. Sci. USA 90:10494, 1993); the model for immune complex alveolitis and dermal vasculitis by Mulligan *et al.* (J. Clin. Invest. 88:1393, 1991); the lymphocyte trafficking model of Hickett *et al.* (J. Clin. Invest. 98:2688, 1996); the IgE-mediated skin reaction model of Wada *et al.* (J. Med. Chem. 39:2055, 1996); and the collagen-induced arthritis and delayed-type skin hypersensitivity models of Zeidler *et al.* (Autoimmunity 21:245, 1995). All the aforelisted descriptions of animal models are hereby incorporated herein by reference in their entirety. Other animal models will also find use for testing the selectin inhibitors of the presently claimed invention.

IV. Uses for Polymerized Liposomes

A. Research Use

The lipid compositions of the present invention can be used to characterize the nature of binding between putative ligand-receptor binding cells. For example, a newly isolated protein receptor that binds isolated neutrophils or HL-60 cells in a manner capable of inhibition by the liposomes of this invention will be suspected as a selectin or similar receptor. A newly isolated mucin that binds HUVEC or cells transfected with selectin in a manner capable of inhibition by liposomes of this invention will be suspected of being a selectin ligand. Adhesion or activation of one cell by another in a manner capable of inhibition by liposomes of this invention will be suspected of being mediated by selectin-ligand coupling or similar receptor-ligand coupling.

B. Diagnostic Use

The lipid compositions of the present invention can also be used for the detection of human disorders in which the ligands for the selectins might be defective. Such disorders would most likely be seen in patients with increased susceptibility to infections involving an abnormality in leukocyte migration or lymphocyte activation.

For *in vitro* diagnostic procedures, cells to be tested are collected from blood, separated by Ficoll-Hypaque™ centrifugation or similar means, and then tested for their ability to bind a liposome with selectin binding activity. The liposome may be labeled with a radioisotopic or fluorescent marker, or if based on diyne chemistry, monitored by way of its intrinsic color. Direct binding of the composition to the cells can provide a measure of selectin on the cell surface. In one illustration, T cells or cells dispersed from a tumor biopsy are isolated and the composition is used to measure the density of selectin. In another illustration, the composition is used in a mixed leukocyte population to count the number of cells expressing selectin.

For *in vivo* diagnostic procedures, the lipid composition is labeled by conjugation with or encapsulation of a suitable agent. Radioisotopes such as ¹¹¹In or ⁹⁹Tc can be used as labels for scintigraphy, or non-radioactive dense atoms can be used to enhance x-ray contrast. The composition is administered intravenously at a peripheral site or via local intubation. Abnormal localization at a particular site may reflect unusual cell trafficking or activation with clinical implications.

C. Therapeutic Use

Since the selectins have several functions related to leukocyte adherence, inflammation, and coagulation, compounds that interfere with binding of P-selectin, L-selectin, or E-selectin can be used to modulate the pathological consequences of these events.

An inflammatory response can cause damage to the host if unchecked, because leukocytes release many toxic molecules that can damage normal tissues. These molecules include proteolytic enzymes and free radicals. Examples of pathological situations in which leukocytes can cause tissue damage include injury from ischemia and reperfusion, bacterial sepsis and disseminated intravascular coagulation, adult respiratory distress syndrome, rheumatoid arthritis, and atherosclerosis.

Reperfusion injury is a major problem in clinical cardiology. Therapeutic agents that reduce leukocyte adherence in ischemic myocardium can significantly enhance the therapeutic

efficacy of thrombolytic agents. Thrombolytic therapy with agents such as tissue plasminogen activator or streptokinase can relieve coronary artery obstruction in many patients with severe myocardial ischemia prior to irreversible myocardial cell death.

However, many such patients still suffer myocardial necrosis despite restoration of blood

5 flow. Reperfusion injury is known to be associated with adherence of leukocytes to vascular endothelium in the ischemic zone, presumably in part because of activation of platelets and endothelium by thrombin and cytokines that makes them adhesive for leukocytes (Romson *et al.*, Circulation 67:1016, 1983). The adherent leukocytes can migrate through the

10 endothelium and destroy ischemic myocardium just as it is being rescued by restoration of blood flow. Ischemia may occur pursuant to a myocardial infarction or as a result of complications of surgery, such as deep vein thrombosis. Another inflammatory condition of concern in cardiology is restenosis.

There are a number of other common clinical disorders in which ischemia and reperfusion results in organ injury mediated by adherence of leukocytes to vascular surfaces.

15 including strokes; mesenteric and peripheral vascular disease; organ transplantation; and multiple organ failure following circulatory shock. Bacterial sepsis and disseminated

intravascular coagulation often exist concurrently in critically ill patients. These conditions are associated with generation of thrombin, cytokines, and other inflammatory mediators, activation of platelets and endothelium, and adherence of leukocytes and aggregation of

20 platelets throughout the vascular system. Leukocyte-dependent organ damage is an important feature of these conditions.

Adult respiratory distress syndrome is a devastating pulmonary disorder occurring in patients with sepsis or following trauma, which is associated with widespread adherence and aggregation of leukocytes in the pulmonary circulation. This leads to extravasation of large

25 amounts of plasma into the lungs and destruction of lung tissue, both mediated in large part by leukocyte products.

Tumor cells from many malignancies (including carcinomas, lymphomas, and sarcomas) metastasize to distant sites through the vasculature. The mechanisms for adhesion of tumor cells to endothelium and their subsequent migration are not well understood, but

30 may be similar to those of leukocytes in at least some cases. The association of platelets with metastasizing tumor cells has been well described, suggesting a role for platelets in the spread of some cancers. It has been reported that P-selectin binds to tumor cells in human carcinoma tissue sections and cell lines derived from carcinomas (Aruggo *et al.*, Proc. Natl.

Acad. Sci. USA 89:2292, 1992). In addition, certain tumors may themselves express selectins or selectin ligands, which may participate in the adherence of metastasizing cells to endothelial cells or HEV at a new site.

Antagonists of P-selectin may be beneficial for blocking platelet-leukocyte interaction as thrombi develop (Welpy *et al.*, Biochem. Biophys. Acta 117:215, 1994). In baboons, administration of anti P-selectin decreased fibrin deposition into Dacron graft implants without diminishing platelet accumulation into the grafts (Palabrica *et al.*, Nature 359:848, 1992). The results suggest that the trapping of leukocytes, via interaction with platelets, may contribute to the deposition of fibrin. Blocking P-selectin may prevent this interaction and may have value as an anti-thrombogenic therapy.

To the extent that the initiation of an acute allograft or xenograft rejection involves selectin-mediated recruitment of inflammatory or immune mediator cells, selectin antagonists can be brought to bear in the few days after engraftment.

Antagonists of P-, E-, and L-selectin are also of interest in palliating autoimmune diseases. For a review of the role of adhesion molecules in these diseases, the reader is referred to Murray (Semin. Arthritis Rheum. 25:215, 1996).

Rheumatoid arthritis is characterized by symmetric, polyarticular inflammation of synovial-lined joints, and may involve extraarticular tissues, such as the pericardium, lung, and blood vessels. Adhesion molecules appear to play an important role (Postigo *et al.*, Autoimmunity 16:69, 1993). Soluble selectins are present in the synovial fluid and blood of affected patients, correlating with elevated ESR (erythrocyte sedimentation rate) and synovial PMN count (Carson *et al.*, J. Rheumatol. 21:605, 1994). Conventional antirheumatic therapy may modify synovial inflammation by altering leukocyte adhesion. Corticosteroids, gold compounds, and colchicine downregulate endothelial expression of selectins (Corkill *et al.*, J. Rheumatol. 18:1453, 1991; Molad *et al.*, Arthritis Rheum. 35:S35, 1992).

Systemic lupus erythematosus is characterized by formation of antinuclear antibodies and manifest by inflammatory lesions on the skin and throughout the body. Selectin expression is increased on dermal vessel endothelial wall of patients with increased disease severity (Belmont *et al.*, Arthritis Rheum. 37:376, 1994). Sjoren's syndrome, autoimmune thyroid disease, multiple sclerosis, and diabetes are other conditions with a heavy implication of altered adhesion proteins such as ICAM-1, LFA-1 and LFA-3, VCAM-1, and selectins (Murray, *supra*), and may be amendable to therapy with selectin inhibitors.

Asthma is characterized by airway obstruction, inflammation, and increased responsiveness to a variety of stimuli, manifest by episodes of cough, dyspnea, and wheezing. The steps proposed in chronic airway inflammation include inflammatory stimulus triggering release of mediators, followed by activation of the leukocyte-endothelial adhesion cascade resulting in leukocyte adhesion to the endothelium. Adhesion molecules implicated include selectins, VCAM-1, and ICAM-1 which may be up-regulated following allergen challenge (Pilewski *et al.*, Am. Rev. Respir. Dis. 148:S31, 1993).

D. Timing and Objectives of Treatment

An effective amount of lipid compositions (See e.g., Example 6 and discussion below) may be used for treating an individual for a condition wherein etiology involves altered cell traffic or activation, mediated in part by selectins.

An "individual" treated by the methods of this invention is a vertebrate, particularly a mammal (including farm animals, sport animals, and pets), and typically a human.

"Treatment" refers to clinical intervention in an attempt to alter the natural course of the individual being treated, and may be performed either for prophylaxis or during the course of clinical pathology. Desirable effects include preventing occurrence or recurrence of disease, alleviation of symptoms, diminishment of any direct or indirect pathological consequences of the disease, such as hyperresponsiveness, inflammation, or necrosis, preventing metastasis, lowering the rate of disease progression, amelioration or palliation of the disease state, and remission or improved prognosis. The "pathology" associated with a disease condition is anything that compromises the well-being, normal physiology, or quality of life of the affected individual.

Treatment is performed by administering an effective amount of a lipid composition of this invention. An "effective amount" is an amount sufficient to effect a beneficial or desired clinical result, and can be administered in one or more doses.

The mode of treatment contemplated by the present invention include but are not limited to the following:

1. Inhibiting leukocyte adhesion or migration, comprising administering a selectin inhibitor so as to inhibit binding between a vascular endothelial cell and a leukocyte selected from the group consisting of neutrophils, monocytes, eosinophils, and lymphocytes bearing a

selectin ligand, thought to be memory T cells. The inhibiting can be performed either by introducing the inhibitor into an environment where the interacting cells come into contact, particularly near the affected site, or contacting the cell bearing the selectin with the inhibitor in the absence of the cell bearing the ligand.

5 2. Inhibiting platelet aggregation or fibrin deposition by administering a selectin inhibitor to an environment containing platelets or susceptible of accumulating platelets.

 3. Inhibiting leukocyte adhesion or migration, comprising administering an selectin inhibitor so as to inhibit binding between a lymphocyte, neutrophil or monocyte and an endothelial cell or lymphatic tissue, particularly an HEV cell.

10 4. Inhibiting lymphocyte adhesion, migration, or activation, comprising administering an selectin inhibitor to the lymphocyte.

 5. Inhibiting metastasis of a tumor suspected of expressing a selectin ligand or receptor by administering an inhibitor for the selectin to the tumor or to the circulation.

 The criteria for assessing response to therapeutic modalities employing the lipid
15 compositions of this invention are dictated by the specific condition. For example, the treatment to prevent extension of myocardial infarction can be monitored by serial determination of marker enzymes for myocardial necrosis, and by EKG, vital signs, and clinical response. Treatment of acute respiratory distress syndrome can be monitored by following arterial oxygen levels, resolution of pulmonary infiltrates, and clinical improvement
20 as measured by lessened dyspnea and tachypnea. Other conditions treated using the methods of this invention are measured according to standard medical procedures appropriate for the condition.

E. Pharmaceutical Preparations and Administration

25 Compositions prepared for use according to the present invention can be prepared for administration to an individual in need thereof, particularly humans, in accordance with generally accepted procedures for the preparation of pharmaceutical compositions. Preferred methods for preparing liposomes described herein are sufficiently flexible that batch sizes from 5 ml to several liters or more can be prepared reproducibly and under sterile conditions.

30 General procedures for preparing pharmaceutical compositions are described in Remington's Pharmaceutical Sciences, E.W. Martin ed., Mack Publishing Co., PA. Liquid pharmaceutically administrable compositions can, for example, be prepared by dispersing a liposome in a liquid excipient, such as water, saline, aqueous dextrose, or glycerol. The

liposome suspension may include lipid-protective agents to protect lipids against free-radical and lipid-peroxidative damages on storage. Lipophilic free-radical quenchers, such as alphotocopheral and water-soluble iron-specific chelators, such as ferrioxamine, can be used. One of the advantages of the polymerized lipid compositions of the present invention is stability against many of the usual degradative effects that accumulate upon storage. The composition may optionally also contain other medicinal agents, pharmaceutical agents, and carriers.

Compositions for injection can be supplied as liquid solutions or suspensions, or as solid forms suitable for dissolution or suspension in liquid prior to injection. For administration to the trachea and bronchial epithelium, a preferred composition is one that provides either a solid or liquid aerosol when used with an appropriate aerosolizer device. Although not required, pharmaceutical compositions are in some instances supplied in unit dosage form suitable for administration of a precise amount.

The route of administration of a pharmaceutical composition depends, inter alia, on the intended target site, clinical condition, and the nature of the condition being treated. Intravenous or intralymphoid administration or injection directly into an affected site are the most usual routes. Pulmonary administration by aerosol is conducted using a nebulizer device. Apparatus and methods for forming aerosols are described in Kirk-Othmer, "Encyclopedia of Chemical Technology," 4th Ed., Vol. 1, Wiley NY, pp. 670-685, 1991.

The size of the dose is selected taking into account the expected volume of distribution of the composition before reaching the intended site of action, and then providing sufficient inhibitor (in nM sugar equivalent) to meet or exceed the IC_{50} concentration as measured in an appropriate cell bioassay, typically at about 2-20 times IC_{50} concentration. In planning the dose, it may not be necessary to completely block all of the selectin receptors. For normal healing, at least some leukocytes may need to migrate to the affected site. The amount of inhibitor is adjusted accordingly.

The assessment of the clinical features and the design of an appropriate therapeutic regimen for the individual patient is ultimately the responsibility of the prescribing physician.

The foregoing description provides, inter alia, a detailed explanation of how lipid compositions can be used to inhibit cellular events mediated by receptor binding. It is understood that variations may be made with respect to structure of the composition or its implementation without departing from the spirit of this invention.

EXPERIMENTAL

The following examples are provided in order to demonstrate and further illustrate certain preferred embodiments and aspects of the present invention and are not to be construed as limiting the scope thereof.

5 In the experimental disclosure which follows, the following abbreviations apply: N (normal); M (molar); mM (millimolar); μ M (micromolar); mol (moles); mmol (millimoles); μ mol (micromoles); nmol (nanomoles); pmol (picomoles); g (grams); mg (milligrams); μ g (micrograms); ng (nanograms); l or L (liters); ml (milliliters); μ l (microliters); cm (centimeters); mm (millimeters); μ m (micrometers); nm (nanometers); i.d. (interior diameter);
10 μ Ci (microcurie); kDa (kilodalton); $^{\circ}$ C (degrees Centigrade); J (Joule); mm Hg (millimeters of mercury); UV (ultraviolet); IC₅₀ (50% inhibitory constant); PDA (diacetylene monomer); BSA (bovine serum albumin); ¹²⁵I-BSA (iodine 125-labeled BSA); pH (hydrogen ion concentration); PSGL-1 (P-selectin glycoprotein ligand 1); NHS (N-hydroxy succinimide);
15 sLe^x (sialyl Lewis X); CO₂ (carbon dioxide); PBS (phosphate buffered saline); HEV (high endothelial venules); WBC (white blood cell); TDC (thoracic duct lymphocytes); SRL (specific lung resistance); EKG (electrocardiogram); MI (myocardial ischemia); TEM (transmission electron microscopy); Sigma (Sigma Chemical Co., St. Louis, MO); Perkin-Elmer (Perkin-Elmer Co., Norwalk, CT); Fisher (Fisher Scientific, Pittsburgh, PA); Farchan Laboratories (Farchan Laboratories, Inc., Gainesville, FL); Park Scientific Instrument (Park
20 Scientific Instruments, Sunnyvale, CA); Biorad (Bio-Rad Laboratories, Hercules, CA); Gelman (Gelman Sciences, Ann Arbor, MI); Pierce (Pierce, Rockford, Ill); and Bellco Glass (Bellco Glass Inc., Vineland, NJ).

EXAMPLE 1

25 Development of two-component glycoliposomes

Glycoliposomes were formed by attaching a carbohydrate component to a polymerizable lipid, mixing with a second polymerizable lipid with a polar head group, forming liposomes, and then polymerizing the lipids.

30 Figure 4 shows the sialyl Lewis X (sLe^x) tetrasaccharide (structure 1) in comparison with the components assembled into liposomes. The carbohydrates labeled as 2a (an sLe^x analog), 3a (lactose), and 4a (maltose) were used for synthesizing the polymerizable glycolipids, hereafter designated as 2b, 3b and 4b, respectively. The precursor polymerizable

lipid was 10,12-pentacosadiynoic acid (PDA), which was conjugated to the carbohydrate by standard techniques. The second polymerizable lipid used during liposome formation was either compound 5 (PDA), which comprises a negatively charged headgroup, or compound 6, which comprises a polar but uncharged headgroup.

5 Figure 2 depicts an expanded view of polymerized glycoliposomes, containing either compounds 2b and 5 (Figure 2A) or 2b and 6 (Figure 2B). The polymerized glycoliposomes were formed as follows: various molar percentages of lipids were prepared so as to give 1mM solutions in total lipid while varying the percentages of glycolipids in the range 0.5 to 50%. The glycolipids were formed into liposomes by the probe sonication method (R.R.C. New, pp. 33-104, in "Liposomes: a practical approach." Oxford U. Press, 1990). The lipids
10 appeared to be miscible based on an analysis of their Langmuir isotherms (G.L. Gaines, in "Insoluble monolayers at liquid-gas interfaces," Wiley NY, 1966).

 Polymerization of the liposomes was carried out by exposure of the aqueous solutions to UV light at 254 nm (Hub *et al.*, Angew. Chem. Int. Ed. Engl. 19:938, 1980; Spevak *et al.*,
15 J. Amer. Chem. Soc. 115:1146, 1993). Polymerization of lipid diacetylenes requires the monomers to adopt a solid analogous state. The carbohydrate percentages reported here are estimates of the sugar groups appearing on both the inner and outer liposome surfaces. With percentages of the glycolipid component above approximately 40%, polymerization was substantially inhibited. This is rationalized by the steric crowding of adjacent carbohydrate
20 headgroups which prevent the proximal diacetylenes from polymerizing.

 Characterization of the polymerized glycoliposomes by transmission electron microscopy (TEM) showed that the preparation consisted of spheres between 20-100 nm in diameter.

25 EXAMPLE 2

Bioassay for selectin inhibition activity

 Ability of the compositions prepared in Example 1 to inhibit selectin binding was tested in a standard bioassay. The assay for measuring P-selectin binding to HL-60 cells was
30 taken from the description in Brandley *et al.* (Glycobiol. 3:633, 1993). Briefly, P-selectin chimera is allowed to form a complex with biotinylated goat F(ab') anti-human IgG Fc and alkaline phosphatase-streptavidin, and is preincubated with inhibitors before mixing with HL-60 cells. The cells were pelleted by centrifugation and washed with PBS. Chromagen was

added and the color that developed was read as an OD at 405 nm. All assays were run in quadruplicate.

Figure 5 shows the inhibition titration curve for various polymerized glycoliposome preparations containing 5% carbohydrate-linked lipid. Open triangles: sLe^x analog conjugate plus acidic lipids. Open circles: sLe^x analog conjugate plus neutral lipids. Closed circles: lactose conjugate plus acidic lipids. Squares: maltose conjugate plus acidic lipids. It is evident from the results of this assay that the presence of the acidic lipid is critical for measurable inhibition, even when the most effective carbohydrate conjugate of those tested, the sLe^x analog, is used. The neutral disaccharides lactose and maltose also have selectin inhibition activity when used alongside acidic lipids. All the compositions having a saccharide and a negatively charged lipid inhibited P-selectin binding in a dose-dependent fashion.

Figure 6 shows the concentration giving 50% inhibition (IC₅₀) for various polymerized glycolipid compositions. The IC₅₀ values are based on the total concentration of glycolipid. No reduction was made for any glycoside that may be inaccessible due to incorporation into the inner layer of the liposome. Therefore, these IC₅₀ values represent an upper limit of the actual glycoside available for binding.

The left panel of Figure 6 is a titration analysis of the optimal proportion of carbohydrate lipid to total lipid in the composition. This experiment was conducted with the sLe^x analog lipid conjugate, with the balance of the composition being the lipid having the carboxylic acid headgroup. It is evident that the optimal percentage is about 5%, although compositions up to at least 50% contain inhibitory activity, and compositions up to about 20% have inhibitory activity in the nM range. Although it is not necessary to understand the mechanism in order to use the present invention, and it is not intended that the present invention be so limited, it is contemplated that the decrease in inhibitory activity at the higher percentages correlates with the increased difficulty in polymerizing these compositions, which is attributed to steric hindrance by the carbohydrate. The 2 nM IC₅₀ for the 5% composition contrasts by about 1 to 5 x 10⁶ with values obtained in this assay for sLe^x monomer.

The right panel of Figure 6 is a comparison of the IC₅₀ for various compositions with different carbohydrate constituents. Both lactose and maltose provide significant inhibitory activity (15 nM and 200 nM respectively) when provided in the context of acidic lipids. The value for lactose in particular compares favorably with that for sLe^x compositions. The last

two bars show the lack of detectable inhibition by polymerized liposomes made with acidic or neutral lipids alone.

Thus, both a suitable carbohydrate and a separate negatively charged lipid were applied in these preparations to provide optimal selectin inhibition activity. In hindsight, we speculate that the binding of other inhibitory compounds, such as certain types of heparin, inositol hexakis phosphate, sulphoglucuronyl glycolipids, fucoidan, sulfatides and an sLe^x-RGD conjugate, can be explained as a combination of a carbohydrate or carbohydrate-like molecules and separately spaced multiple acid groups.

The possibility of intercalation of the liposomes into the cells, thereby effecting their ability to bind P-selectin, was also addressed. The cells were pretreated with the liposomes and washed to remove the liposomes prior to the addition of the P-selectin chimera. This did not result in any reduction in selectin binding to the cells. The inhibition was unaffected in experiments where the reagents and inhibitors were added simultaneously to the microtiter plates.

By way of comparison, the level of sLe^x or sLe^x analog presented as a monomer required to reach IC₅₀ in this assay was approximately 1 to 5 mM. The relative improvement imparted by incorporation in the polymerized liposome was approximately 10⁶-fold.

EXAMPLE 3

Requirement and sufficiency for negatively charged lipids

Additional polymerized glycoliposome compositions were prepared for testing in a different assay system.

The assay was an ELISA in which the polymerized liposomes were tested for an ability to inhibit the binding of selectin chimera to isolated GlyCAM-1. A full description is provided in Bertozzi *et al.* (Biochemistry 34:14275, 1995). Briefly, a crude preparation of GlyCAM-1 was obtained from mouse serum by extraction with 2:1 chloroform/methanol, recovery of the aqueous phase, and concentration. This mucin acts in this assay as a ligand for any of the three selectins. Microtiter plates were coated with polyclonal antibody specific for the peptide backbone of the mucin, overlaid with the mucin, and then washed. Meanwhile, a complex was formed between: a) a chimera of the respective selectin fused to the Fc region of the human IgG heavy chain; b) biotinylated F(ab') anti-Fc; and c) streptavidin-alkaline phosphatase conjugate. This solution (70 µL) was combined with 70 µL

of inhibitor and incubated for 30 minutes. then transferred to the microtiter plate wells. After 30 minutes at room temperature. the wells were washed. and developed with the enzyme substrate p-nitrophenyl phosphate.

Figure 7 shows the polymerized liposomes prepared for testing. Five different groups were prepared having either no oligosaccharide (Group 1), or one of four different oligosaccharide conjugated lipids at a relative molar concentration of 5% (Groups 2-5). Within each group, the substituent on the lipids not conjugated with oligosaccharide (shown as an "X" in the diagram) was varied as follows:

- an amine, which has a positive charge at neutral pH;
- a hydroxyl group, which is neutral but electronegative;
- a carboxylic acid, which has a negative charge at neutral pH; or
- a mixture comprising either 5% or 50% lipid with the oxyacid sulfate, the balance being lipid with a hydroxyl head group.

These compositions gave the following results in the selectin inhibition assay:

Group	Carbohydrate lipid substituent	Other lipid substituent	Inhibitory Activity IC ₅₀ in μ M		
			L-selectin	E-selectin	P-selectin
1	(none)	-CONHCH ₂ CH ₂ NH ₂	> 250	> 250	> 250
		-CONHCH ₂ CH ₂ OH	> 250	> 250	> 50
		-COOH	> 250	> 250	> 100
		-CONHCH ₂ CH ₂ OSO ₃ ⁻ (A)	> 250	> 250	> 18
		-CONHCH ₂ CH ₂ OH (B) (A:B = 5:95)			
		-CONHCH ₂ CH ₂ OSO ₃ ⁻ (A)	7.5	> 50	4.4
		-CONHCH ₂ CH ₂ OH (B) (A:B = 50:50)			
2	5% sLe ^x analog	-CONHCH ₂ CH ₂ NH ₂	> 12.5	> 12.5	> 12.5
		-CONHCH ₂ CH ₂ OH	1.12	> 12.5	1.5
		-COOH	0.50	> 2.5	0.47
		-CONHCH ₂ CH ₂ OSO ₃ ⁻ (A)	0.26	0.45	0.18
		-CONHCH ₂ CH ₂ OH (B) (A:B = 50:50)			
3	5% sulfo Le ^x analog	-CONHCH ₂ CH ₂ NH ₂	> 12.5	> 12.5	> 12.5
		-CONHCH ₂ CH ₂ OH	0.26	0.38	0.18
		-COOH	0.26	0.68	0.28
		-CONHCH ₂ CH ₂ OSO ₃ ⁻ (A)	0.20	n.d.	n.d.
		-CONHCH ₂ CH ₂ OH (B) (A:B = 50:50)			
4	5% lactose	-CONHCH ₂ CH ₂ OH	> 12.5	> 12.5	> 12.5
		-COOH	1.80	> 12.5	0.50
5	5% maltose	-CONHCH ₂ CH ₂ OH	> 12.5	> 12.5	3.0
		-COOH	3.0	> 12.5	1.3

The IC₅₀ values are all based on the total amount of liposome bound carbohydrate except in Group 1, where the values are calculated from the total amount of matrix head groups.

The results support the following conclusions. First, the sulfated carbohydrate sulfo Le^x analog has a very low IC₅₀ (high inhibitory capacity) for L-, E- or P-selectin in a context of acidic or polar lipids (but not positively charged lipids). Where the saccharide was the non-sulfated sLe^x analog, an acidic

neighboring lipid was required for full inhibitory activity, which is selective for L- and P-selectin. Sulfate lipids support sLe^x binding better than carboxylate lipids, even at a relative proportion of 50%. As in the preceding example, the presence of acid lipids turn ineffective neutral disaccharides like lactose and maltose into effective inhibitors. This effect occurred only for L- and P-selectin, since none of the neutral disaccharide compositions inhibited E-selectin binding. The contributory effect of acid groups to the binding of L- and P-selectin is consistent with the working hypothesis that the lipid acid groups fulfill a selectin binding requirement equivalent to what is provided by sulfotyrosine or its equivalent in the biological ligands.

This mixed construction approach combined with a simple plate-binding assay provides a rapid method for identifying carbohydrate-acid group combinations that are capable of selectively inhibiting the binding of different selectin-ligand pairs.

Interestingly, the sulfated lipid by itself provided substantial binding activity for L- and P-selectin in this ELISA assay. The results shown in Table 1 for Group 1 were calculated in terms of the μ M concentration of the lipid headgroup, for comparison on a substituent basis with the other compositions where the oligosaccharide is treated as the limiting substituent. However, there are 20 times more lipid headgroups per liposome in Group 1 than there are carbohydrates per liposome in Groups 2-5. Normalizing the values for Group 1 for comparison with the other groups on a per-liposome basis, the 50% sulfate lipid composition in Group 1 had inhibitory activity for L- and P- selectin of 0.38 and 0.22, respectively. This compares favorably with the IC₅₀ of the oligosaccharide liposomes.

EXAMPLE 4

Cell activity assays confirm biological efficacy of glycoliposomes and demonstrate inhibitory capacity of oxyacid liposomes for E-selectin

Glycoliposomes containing 5% sulfo Le^x analog and 95% hydroxyl-terminated lipid were tested in a flow adhesion assay (Alon *et al.*, Nature 374:539. 1995). Briefly, P-selectin chimera was immobilized in a flow chamber and the

affinity of HL-60 cells for this substrate was monitored for their ability to roll slowly along on the surface. The interaction was specific for the PSGL-1 mucin domain on the HL-60 cells and the inhibitor's ability to block cell adhesion under physiological flow rather than under static conditions. At a glycolipid concentration of 1 μ M, this glycoliposome formulation was able to completely inhibit HL-60 cell rolling on P-selectin surfaces. The control liposome (without the carbohydrate) had no effect.

The same liposome formulation was tested in the Stamper-Woodruff lymphocyte homing assay (Stamper *et al.*, J. Exp. Med. 144:828, 1976). This assay measures ability of lymphocytes to home into lymph nodes through high endothelial venules (HEV), a process known to be mediated by L-selectin. Thoracic duct lymphocytes (TDC) were counted on fixed sections of HEV in the presence of the liposomes. The 5% glycoliposome completely inhibited the TDC from binding to HEV at a concentration of 1 μ M. The control liposome had no effect.

Liposomes comprising carbohydrate alone, oxyacid groups alone, and combinations of carbohydrates and oxyacid groups were tested in human *in vitro* leukocyte-endothelium selectin rolling assays. The inhibition of leukocyte rolling on selectin expressing monolayers, by the liposome assemblies, was examined for all three selectins. L- E- and P-selectin adhesion were examined where the effects of compound treatment was record to video tape and quantified by computer image analysis methods. The systems include neutrophil-IL-1 β activated HUVEC rolling adhesion; neutrophil-thrombin activated platelet rolling; E-selectin transfectant-neutrophil rolling; as well as neutrophil-neutrophil rolling. Relative inhibitions were determined for the inhibitory liposomes with dose responses and estimated IC₅₀ values being determined based on the relative number of leukocytes adhering (rolling and sticking) to the compound-treated vs. control assays. Results are as described above and shown in Figures 11-13.

A. Neutrophil isolation

Neutrophils were isolated from human peripheral blood. Briefly, blood was collected into citrate anti-coagulant tubes (Becton Dickinson), diluted 1:2 at room temperature in sterile HEPES (20 mM) buffered HBSS (pH 7.0) (Fisher Scientific).

underlayered with Histopaque 1077 and Histopaque 1117 (Sigma), and centrifuged at 2,300 RPM for 30 minutes at room temperature. Neutrophils were collected from the Histopaque 1117/1077 interface.

Neutrophils, that were collected as indicated above, were bound to the interior of glass capillary tubes to form monolayers. This provided a direct means of examining the effects of the liposomes on neutrophil-neutrophil adhesive interactions that lead to amplified recruitment.

B. HUVEC cultures and activation

Human umbilical-cord endothelial cells (HUVECs), which were Factor VIII and LDL-receptor positive, were cultured for 24 hours on the interior surface of 1.3 mm internal diameter borasilicate glass capillary tubes in endothelial-cell growth media (EGM, Clonetecs). The HUVECs were then treated for 1 hour at 37°C with human rIL-1 β (1 unit/ml) (Genzyme), washed and incubated for the remaining 3 hours of the 4 hour incubation at 37°C in EGM. The rIL-1 β treatment resulted in high HUVEC levels of E-selectin expression.

C. Platelet collection and activation

Platelets were isolated from human plasma that had been previously cleared of leukocytes by centrifugation at 300 g. The platelets were resuspended in HBSS and kept on ice until used in the capillary tube assay. Platelets were coated onto the internal surface of collagen coated capillary tubes and activated to express P-selectin using 1 U/ml of thrombin with a 10 minute preincubation.

D. Liposome treatment

Liposomes were individually preincubated with the human neutrophils for 10-15 minutes at room temperature before infusion, without washing, into the shear system loop. Liposomes were preincubated with HUVECs, platelets, or neutrophils respectively, at several concentrations and also infused into the loop for the same final liposome concentration.

E. *In vitro* shear assay

After activation, the HUVEC, platelet, or neutrophil containing capillary tubes were connected to the assay tubing to form a closed loop in which medium and cells could be recirculated; the tube was then mounted on an inverted microscope stage. Using a variable speed peristaltic pump, flow was regulated to simulate *in vivo* shear conditions (*i.e.*, 1.8 - 2 dynes/cm²). Isolated human neutrophils were infused into the system at a 2x10⁶ cell/ml in sterile HEPES buffered (20 mM) HBSS (pH 7.0) plus 1% human serum. Rolling was established and continuously monitored for the duration of the experiment while being videotaped for off-line analysis.

F. Analyses of neutrophil rolling

The number of neutrophils interacting with activated HUVECs, platelets or neutrophils were quantified at 1 minute intervals using NIH IMAGE software, Montana ImmunoTech Inc. macros and an Apple Computer PowerMac 7100 (66). The number of interacting neutrophils were quantified, within 350 μ m (horizontal) by 250 μ m (vertical) video-microscopic fields.

EXAMPLE 5

Alternative saccharide components

Further refinement of the carbohydrate component of polymerized liposomes is conducted along several fronts.

In one experimental series, the prototype oligosaccharides sLe^x and sulfo Le^x are dissected into various substituents and tested in independent compositions. Figure 8 shows some monosaccharide and disaccharide lipid conjugates of interest. Other saccharides of interest are lactosamine, 3' sialyl lactosamine, and 3' sialyl lactose. The identification of active subcomponent saccharides has two purposes. One is to further elucidate the binding requirements for each selectin, which can then be used to develop inexpensive analog structures with enhanced binding or

selectin specificity. Another is to identify mono- and disaccharides that can be used in a mixed saccharide liposome, as explained below.

In another experimental series, other oligosaccharides believed to have equal or better activity than the prototypes as monomers are tested in liposome compositions to determine if the activity can be enhanced further. Conjugates of interest are shown in Figure 9. Other conjugates of interest are various sLe^x analogs and other structures listed elsewhere in the disclosure.

The conjugates are formed similarly to those in the previous examples: by formation of peracetylated beta-NAc-allyl glycoside, combined with cystamine hydrochloride under UV light, and then coupled directly with the activated acid of PDA.

Mixed saccharide liposomes have different saccharides conjugated to different lipids in the composition. It is proposed that the different saccharides can work in concert to supply the carbohydrate requirement for selectin binding, when presented in the context of other lipids satisfying the anionic binding requirement in a polymerized lipid sheet. Of particular interest is a combination of sialic acid and fucose, since these are believed to be the residues in sLe^x responsible for selectin binding.

The sialic acid conjugate is prepared according to the standard method outlined in Spevak *et al.*, J. Amer. Chem. Soc. (1993) 115:1146. The fucose conjugate is prepared as follows: first, the perbenzoylated, glycosylchloride of fucose is C-allylated by trimethylallylsilane and trimethylsilyltriflate (Hosomi *et al.*, Tetrahedron Lett. 2383, 1984) to give the C-glycoside. This compound is deprotected by sodium/ammonia. The perbenzoylated C-glycoside of fucose is dissolved in t-butanol and added to refluxing, anhydrous ammonia, protected from moisture. Solid sodium metal is then added until the blue color persists for at least 20 minutes. The reaction is then quenched with ammonium chloride and the ammonia is allowed to evaporate. The solid residue is dissolved in water, brought to about pH 2 with concentrated HCl and extracted with ethyl acetate several times. The combined organic solutions are dried with magnesium sulfate and filtered. After evaporation the C-glycoside product is purified by flash chromatography. The C-glycoside is dissolved with cystamine-hydrochloride (3 equivalents) in degassed water to give a 1 molar sugar solution. The solution is kept under a

constant blanket of nitrogen and irradiated with UV light (254nm). After 12 hours the solution is neutralized with solid sodium bicarbonate, concentrated and flash chromatographed yielding the amine. This is dissolved in a minimal amount of methanol, added to the solution of NHS-PDA (1.2 equivalents) and stirred for 12 hours. The reaction is diluted with chloroform, washed with saturated, aqueous sodium bicarbonate, then dried with magnesium sulfate and filtered. After evaporation, the crude glycolipid residue is purified with flash chromatography.

Sialic acid conjugate and fucose conjugate are mixed at a ration 1:1 and then combined with PDA at 5 to 10% glycoconjugate as molar percent of total lipid. Vesicle formation and lipid polymerization proceed as normal to form a mixed glycoliposome with a surface structure shown in Figure 10.

The polymerized lipid compositions described in this example are tested according to the assay described in Example 3.

EXAMPLE 6

Therapeutic testing in animal models

Liposome compositions having good inhibition activity in selectin or other receptor binding assays are tested further for their efficacy in disease models. All trials are conducted in accordance and with the approval of the appropriate Animal Use Committee.

Myocardial ischemia and reperfusion injury are modeled according to protocols similar to those of Weyrich *et al.* (J. Clin. Invest. 91:2620, 1993), Murohara *et al.* (Cardiovascular Res. 30:965, 1995), and Ma *et al.* (Circulation 88:649, 1993). Briefly, adult mammals of higher species (typically canine, feline, or ovine) are anesthetized, and a midsternal thoracotomy is performed. A silk ligature is tied around the left anterior descending coronary artery 8-10 mm from the origin. EKG and MABP are continuously monitored. The animals are allowed to stabilize, and then myocardial ischemia (MI) is induced by tightening the ligature to complete occlusion. The test therapeutic agent is given intravenously as a bolus

80 minutes later. At the 90 minute time point, the ligature is untied and the myocardium is allowed to reperfuse for 270 minutes.

The ligature is retightened, and the area at risk is identified by injecting Evans blue. After excision, irreversibly injured parts of the heart are identified by dissection and staining using 0.1% nitroblue tetrazolium, and calculated as a percentage of mass of the organ. The proportional area effected is reduced upon successful treatment. Myeloperoxidase activity in the ischemic myocardium as determined according to Mullane *et al.* (J. Pharmacol. Meth. 14:157, 1985) is preferably also reduced. The ischemic-reperfused coronary endothelium can also be measured for adherence of isolated autologous PMN, and is preferably reduced in the treated animals. The animals are tested in three groups: MI induced and inhibitor treated; MI induced and control treated; and sham MI (operated but without vessel occlusion).

Treated animals in the cited studies responded to 400 µg/kg of sLe^x presented as a phospholipid liposome, or 1 mg/kg of the anti-L-selectin monoclonal antibody DREG-200. In the present experiment, liposomes having oxyacid groups are tested in a range of about 100-4000 µg of total lipid per kg body weight. An equal number of liposomes made of 100% neutral lipids is given at an equal dose (on a per liposome basis) as vehicle control. To the extent that necrosis induced by other types of acute cardiac inflammatory events, such as myocarditis, restenosis and deep vein thrombosis, are mediated by similar mechanisms, the effective doses established in the cardiac reperfusion model may also be considered for these conditions.

Lung reperfusion injury is modeled according to protocols similar to those of Steinberg *et al.* (J. Heart Lung Transplant 13:306, 1994) and Kapelanski *et al.* (J. Heart Lung Transplant 12:294, 1993). Briefly, general anesthesia is induced, and the left lung is exposed by excision of adjacent ribs, intercostal muscles and neurovasculature. After a 30 minute recovery period, animals are selected for continuation that have an arterial oxygen tension above 200 mm Hg and a carbondioxide tension below 45 mm Hg. After systemic heparinization, ischemia of the left lung is initiated by occlusion of the left main pulmonary artery. The period of ischemia is about 3 hours, whereupon the lung is ventilated and permitted to reperfuse. Ten minutes before reperfusion, animals receive a bolus

intravenous infusion of the test therapeutic compound. Ten minutes after the onset of reperfusion, the right pulmonary artery is ligated, and the tip of an endotracheal tube is advanced beyond the orifice of the tracheal bronchus, and the right main bronchus is clamped at end expiration. Physiologic parameters are recorded for 6 hours. Animals are compared on the basis of survival data, plus several of the following: gravimetric lung water, partial pressures of oxygen and carbon dioxide, inert gas shunt, pulmonary vascular resistance, and circulating WBC, neutrophil and lymphocyte count. Sham animals are operated but the pulmonary artery is not ligated - both lungs are ventilated during the 3 hour period, and then worked up as in the test animals.

In the first study cited above, ischemic animals responded to 1 mg/kg of the monoclonal antibody EL-246, specific for L- and E-selectin. In the present experiment, liposomes having oxyacid groups are tested in a range of about 100-4000 µg of total lipid per kg body weight. An equal number of liposomes made of 100% neutral lipids is given at an equal dose (on a per-liposome basis) as vehicle control.

Pulmonary vascular injury induced by hemorrhagic shock is modeled according to protocols similar to those of Kushimoto *et al.* (Thrombosis Res. 82:97, 1996). Briefly, adult rats are anesthetized with pentobarbital, the right carotid artery is cannulated for monitoring blood pressure, and the left femoral artery is cannulated for sampling blood and administering fluids. Phlebotomy is induced by gradual withdrawal of 25 ml blood/kg over 15 minutes using a syringe pump. The mean arterial pressure is maintained between approximately 30-40 mm Hg for 30 minutes, and then the rates are resuscitated with 75 ml/kg lactated Ringer's solution, infused over 30 minutes. Physiological body temperature is maintained during this procedure using a heat lamp. Sham animals are cannulated in the same fashion, but no blood is removed. Pulmonary accumulation of leukocytes, measured as myeloperoxidase activity, and pulmonary vascular permeability to bovine serum albumin (BSA) peaks at 6 hours. The hemorrhagic shock is reversible, because animals surviving the first 6 hours and allowed to recover survive for at least another 5 days.

The therapeutic compound is tested by administering boluses of test compound through the femoral artery cannula at regular intervals through the

critical period (0, 2, and 4 hours following fluid resuscitation). ^{125}I -BSA is injected 30 minutes prior to sacrifice at the 6 hour point. A midline laparotomy is performed, blood is withdrawn from the abdominal aorta, and the pulmonary vasculature is perfused with saline via right ventricular puncture. Pulmonary vascular permeability is calculated as a ratio cpm in lung versus plasma, and is an indication of pulmonary vascular damage. Lung samples are homogenized and assayed for myeloperoxidase activity according to Warren *et al.* (J. Clin. Invest. 84:1873, 1989), as an indication of the number of neutrophils in the lung. Reduction of myeloperoxidase activity and/or permeability by the test composition compared with vehicle control is an indication of efficacy.

In the cited study, hemorrhagic animals responded to 1 mg/kg of the monoclonal antibody PB 1.3. In the present experiment, liposomes are tested in a range of about 100-4000 μg of total lipid per kg body weight per administration.

Tumor metastasis is modeled according to protocols similar to those described in PCT application WO 96/34609. This model is based on the highly metastatic BL6 clone of the B16 melanoma cell line (Dr. Jean Starkey, Montana State U., Bozeman MT), or a similar line established and cloned by standard techniques from an excised melanoma or carcinoma. A suspension of metastatic cells is suspended and incubated for 5-10 minutes at 37°C with the therapeutic test compound at various concentrations, or a vehicle control. Following incubation, about 2.5×10^4 cells in a volume of 200 μL are injected into the tail vein of 8 week old syngeneic mice. After about 3 weeks, the animals are sacrificed. Lung and liver are excised and fixed in 10% formaldehyde, and tumor cell colonies are counted under a dissecting microscope. Colonies with a diameter > 1 mm are counted separately from smaller colonies. A positive result is indicated by a substantial reduction in the total number of colonies or in the proportion of larger colonies. Liposome preparations are tested in a range of 50 nM-100 μM final concentration of total lipid in the cell incubation mixture.

Allergic asthma is modeled according to protocols similar to those described in PCT application WO 96/35418. Briefly, adult sheep are selected on the basis of having an established early and late bronchial response to inhaled *Ascaris suum* antigen. Animals are restrained, and the nasal passages are topically anesthetized with lidocaine. The animals are intubated with a cuffed endotracheal tube through

the opposite nostril with a flexible fiber optic bronchoscope as guide. Pleural pressure is estimated with an esophageal balloon catheter. Lateral pressure is measured with a sidehole catheter (i.d. 2.5 mm) advanced through and positioned distal to the tip of the endotracheal tube. The tracheal and pleural pressure catheters are connected to a differential pressure transducer for measuring transpulmonary pressure. Airflow is measured by connecting the proximal end of the endotracheal tube to a pneumotachograph. Pulmonary flow resistance is calculated as the change in transpulmonary pressure divided by the change in flow at mid-tidal volume, averaged over 5 breaths. Thoracic gas volume is measured in a constant-volume body plethysmograph to obtain specific lung resistance (SRL).

Aerosols of test therapeutic suspensions are generated using a nebulizer that provides a median aerodynamic diameter of approximately 3 μm . The nebulizer is connected to a dosimeter system, consisting of a solenoid valve and a source of compressed air. The solenoid valve is activated for 1 second at the beginning of the inspiratory cycle of the respirator. Aerosols are delivered at a tidal volume of 500 ml at a rate of 20 breaths per minute. The test therapeutic compound is administered via nebulizer. To assess bronchial responsiveness, cumulative concentration response curves are determined by measuring SRL immediately after inhalation of buffer, and after each consecutive administration of 10 breaths of increasing concentrations of carbachol, in the range of approximately 0.25% to approximately 4% (wt/vol). The test is discontinued when SRL exceeds 400% of initial value or the maximal dose is reached. Bronchial responsiveness is assessed by determining the point at which SRL reached 400%. Liposome preparations are tested in a range of 50 nM to 100 μM final concentration of total lipid in the aerosol solution.

Arthritis is modeled according to the collagen type-II induced arthritis model of Zeidler *et al.* (Autoimmunity 21:245, 1995). Briefly, groups of age-matched DBA/1 mice are immunized intradermally with 100 μg collagen type II from bovine cartilage, emulsified in complete Freund's adjuvant, followed 18 days later with 50 μg in incomplete Freund's adjuvant. Test therapeutic compositions are administered weekly from about week 4 to about week 8 following the first collagen injection. The disease is assessed daily by visual signs of erythema, and of swelling of one or more joints. Immunological signs of autoimmunity are

monitored by standard immunoassays for serum antibody against collagen type II, collagen type I, and proteoglycans. Reduction in the titers of the autoantibodies, or a delay in the appearance of visual signs of arthritis, are indications of efficacy. Liposomes are tested in a range of about 10-400 μ g of carbohydrate equivalent per kg body weight. In the present experiment, liposomes are tested in a range of about 10-400 μ g of carbohydrate equivalent per kg body weight per administration, or an equal number of control liposomes.

Other established animal models are implemented in the testing of liposomes for the treatment of additional clinical conditions of interest applying the methods and strategies discussed above.

All publications and patents mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described method and system of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in pharmacology, chemistry, biochemistry, and molecular biology or related fields are intended to be within the scope of the following claims.

CLAIMS

We claim:

1. Compositions comprising lipid assemblies, wherein said lipid assemblies comprise:

- 5
- a) a plurality of lipid monomers;
 - b) one or more surface exposed oxyacid groups; and
 - c) one or more surface exposed carbohydrates;

wherein said lipid assemblies are capable of inhibiting the binding between a first cell having a receptor and a second cell having a ligand for said receptor.

10

2. The compositions of Claim 1, wherein said surface exposed oxyacid group is selected from the group consisting of carboxyl groups and groups of the form $(XO_n)(O^-)_p$ where $n+p > 2$ and X is an atom capable of binding three or more oxygen atoms.

15

3. The compositions of Claim 2, wherein said groups of the form $(XO_n)(O^-)_p$ where $n+p > 2$ comprise groups where X is selected from the group consisting of sulphur and phosphorus.

4. The compositions of Claim 1, wherein said surface exposed oxyacid group is covalently attached to said lipid monomers.

20

5. The compositions of Claim 1, wherein said surface exposed carbohydrates comprise neutral carbohydrates.

6. The compositions of Claim 1, wherein said surface exposed carbohydrates comprise neutral carbohydrates selected from the group consisting of maltose and lactose.

25

7. The compositions of Claim 1, wherein said surface exposed carbohydrates are covalently attached to said lipid monomers.

8. The compositions of Claim 1, wherein said receptor comprises a selectin.

9. The compositions of Claim 7, wherein said selectin is selected from the group consisting of P-selectin, L-selectin, and E-selectin.

5 10. The compositions of Claim 1, wherein said receptor is selected from the group consisting of lectins, heparin, heparan sulfate, gangliosides, glycans, glycoproteins, and glycolipids.

11. Compositions comprising one or more polymerized lipid assemblies, wherein said polymerized lipid assemblies comprise:

- 10 a) a plurality of lipid monomers; and
b) one or more surface exposed oxyacid groups;

wherein said polymerized lipid assemblies are capable of inhibiting the binding between a first cell having a receptor and a second cell having a ligand for said receptor.

15 12. The composition of Claim 11, further comprising one or more surface exposed carbohydrates.

13. The composition of Claim 12, wherein said one or more surface exposed carbohydrates are selected from the group consisting of sulfated carbohydrates, fucose, sialylated fucooligosaccharides, sialylated
20 fucooligosaccharide analogs, sulfated fucooligosaccharides, maltose, lactose, sialic acid, glycopeptides, and combinations thereof.

14. The compositions of Claim 11, wherein said surface exposed carbohydrates are covalently attached to said lipid monomers.

25 15. The compositions of Claim 11, wherein said surface exposed oxyacid group comprises groups of the form $(XO_n)(O^-)_p$ where $n+p>2$ and X is an atom capable of binding three or more oxygen atoms.

16. The compositions of Claim 15, wherein said groups of the form $(XO_n)(O^-)_p$ where $n+p>2$ comprise groups where X is selected from the group consisting of sulphur and phosphorus.

17. The compositions of Claim 11, wherein said surface exposed oxyacid group is covalently attached to said lipid monomers.

18. The compositions of Claim 11, wherein said receptor comprises a selectin.

19. The compositions of Claim 18, wherein said selectin is selected from the group consisting of P-selectin, L-selectin, and E-selectin.

20. The compositions of Claim 11, wherein said receptor is selected from the group consisting of lectins, heparin, heparan sulfate, gangliosides, glycans, glycoproteins, and glycolipids.

21. A method for inhibiting the binding between a first cell having a receptor and a second cell having a ligand for said receptor, comprising:

- 15 a) providing:
- i) a sample containing said first cell and said second cell; and
- ii) a polymerized lipid assembly comprising a plurality of lipid monomers and one or more surface exposed oxyacid groups; and
- 20 b) exposing said polymerized lipid assembly to said first cell.

22. The method of Claim 21, wherein said inhibiting the binding between said first cell and said second cell comprises inhibition of cell-cell interactions selected from the group consisting of cell adhesion and cell migration.

23. The method of Claim 21, wherein said polymerized lipid assemblies further comprises one or more surface exposed carbohydrates.

24. The method of Claim 23, wherein said one or more surface exposed carbohydrates are selected from the group consisting of sulfated carbohydrates, fucose, sialylated fucooligosaccharides, sialylated fucooligosaccharide analogs, sulfated fucooligosaccharides, maltose, lactose, sialic acid, glycopeptides, and combinations thereof.

25. The method of Claim 21, wherein said surface exposed carbohydrates are covalently attached to said lipid monomers.

26. The method of Claim 21, wherein said surface exposed oxyacid group comprises groups of the form $(XO_n)(O^-)_p$ where $n+p>2$ and X is an atom capable of binding three or more oxygen atoms.

27. The method of Claim 26, wherein said groups of the form $(XO_n)(O^-)_p$ where $n+p>2$ comprise groups where X is selected from the group consisting of sulphur and phosphorus.

28. The method of Claim 21, wherein said surface exposed oxyacid group is covalently attached to said lipid monomers.

29. The method of Claim 21, wherein said receptor comprises a selectin.

30. The method of Claim 29, wherein said selectin is selected from the group consisting of P-selectin, L-selectin, E-selectin.

31. The method of Claim 21, wherein said receptor is selected from the group consisting of lectins, heparin, heparan sulfate, gangliosides, glycans, glycoproteins, and glycolipids.

32. A method for inhibiting the binding between a first cell having a receptor and a second cell having a ligand for said receptor, comprising:

a) providing:

i) a sample containing said first cell and said second cell; and

ii) a lipid assembly comprising a plurality of lipid monomers, one or more surface exposed oxyacid groups, and one or more surface exposed carbohydrates; and

b) exposing said polymerized lipid assembly to said first cell.

33. The method of Claim 21, wherein said inhibiting the binding between said first cell and said second cell comprises inhibition of cell-cell interactions selected from the group consisting of cell adhesion and cell migration.

34. The method of Claim 32, wherein said surface exposed oxyacid group comprises groups of the form $(XO_n)(O^-)_p$ where $n+p>2$ and X is an atom capable of binding three or more oxygen atoms.

35. The method of Claim 34, wherein said groups of the form $(XO_n)(O^-)_p$ where $n+p>2$ comprise groups where X is selected from the group consisting of sulphur and phosphorus.

36. The method of Claim 32, wherein said surface exposed oxyacid group is covalently attached to said lipid monomers.

37. The method of Claim 32, wherein said surface exposed carbohydrates comprise neutral carbohydrates.

38. The method of Claim 32, wherein said surface exposed carbohydrates comprise neutral carbohydrates selected from the group consisting of maltose and lactose.

39. The method of Claim 32, wherein said surface exposed neutral carbohydrates are covalently attached to said lipid monomers.

40. The method of Claim 32, wherein said receptor comprises a selectin.

41. The method of Claim 40, wherein said selectin is selected from the
5 group consisting of P-selectin, L-selectin, and E-selectin.

42. The method of Claim 32, wherein said receptor is selected from the group consisting of lectins, heparin, heparan sulfate, gangliosides, glycans, glycoproteins, and glycolipids.

FIGURE 1




FIGURE 2







FIGURE 3



The chemical structure shows a repeating unit of a glycosaminoglycan, specifically chondroitin-6-sulfate. It consists of a disaccharide chain. The first sugar is a glucuronic acid unit in its pyranose form, with a carboxylic acid group at C5 and hydroxyl groups at C2, C3, and C6. It is linked via a β-glycosidic bond to the C1 of the second sugar, which is a glucosamine unit in its pyranose form. This second sugar has an acetamido group (NHAc) at C2, a hydroxyl group at C3, and a sulfate group (SO₃Na) at C6. The chain is shown as a repeating unit with a subscript 'n'.


2.

2.




4. Maltose

a. $R = -OH$



5.



6.

FIGURE 5




FIGURE 6




FIGURE 7









FIGURE 8

Selectin Ligand FragmentsTarget Glycolipids

Glucose

N Ac-Glucosamine

Galactose

Lactose

N Ac-Lactosamine

Fucose

Fucose α -3-GlucoseFucose α -4-Glucose

3'-Sialyl lactose

Glc β -1 lipid (1)GlcNAc β -1 lipid (2)Gal β -1 lipid (3)Lac β -1 lipid (4)LacNAc β -1 lipid (5)Fuc β -1 lipid (6)Fuc α -3-Glc β -1 lipid (7)Fuc α -4-Glc β -1 lipid (8)NeuAc β -3'-Lac β -1lipid (9)

FIGURE 9




FIGURE 10





FIGURE 11




FIGURE 12





FIGURE 13



INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/03957

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : A61K 31/70, 31/715, 31/725, 9/127
US CL : 514/25, 53, 54, 56, 57, 61, 62; 424/450
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/25, 53, 54, 56, 57, 61, 62; 424/450

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
WPIDS, MEDLINE, HCAPLUS- cell adhesion inhibition employing assemblies with carbohydrate, oxyacid and lipid moieties.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A,P	Database HCAPLUS on STN, American Chemical Society. AN 1997:594623, SPEVAK et al. 04 September 1997, 'Cross-linked lipid compn. with saccharide and acidic groups for inhibition of selectin binding'. WO 9731625 A1, abstract.	1-42
Y	Database WPIDS on STN, London: Derwent Information Ltd., AN 97-164836 [15], SRIVASTAVA et al. 08 December 1996, 'Glyco-pyranosyl(1-2)glyco-pyranosyl(1-3)glyco-pyranose ether derivs. -e.g. with omega-methoxycarbonyl-octanol, are antiviral agents, notably against HIV, also useful for treatment of obesity and diabetes'. WO 9640700 A1 abstract.	1-42
Y	Database WPIDS on STN, London: Derwent Information Ltd., AN 96-116981 [12], FLITSCH et al. 08 February 1996, 'Regioselective sulphation of vicinal di hydroxy cpd. esp. saccharide - by treating stannylene acetal deriv. with electrophilic sulphating agent, giving high yield'. WO 9603413 A2 abstract.	1-42

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
B earlier document published on or after the international filing date	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
I document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z*	document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means		
P document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

26 APRIL 1998

Date of mailing of the international search report

23/05/98

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT

Authorized officer

M. MORZIN

M. Morzin